CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11307801,1130780113,13,F,,20170717,20150724,20170724,EXP,,DE-ROCHE-1495718,ROCHE,", INGILIZ P, PETERSEN J, PECK-RADOSAVLJEVIC M, WELZEL T, VAN DER VALK M, ZHAO Y, JIMENEZ-EXPOSITO M AND ZEUZEM S DACLATASVIR PLUS SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, IN REAL-WORLD PATIENTS WITH HIVHCV COINFECTION AND ADVANCED LIVER DISEASE. ANTIVIRAL THERAPY 2017;22 (3):225-236.",,,,,Y,,,20170724,,MD,DE,DE,EFAVIRENZ,Abdominal pain;Acute kidney injury;Anaemia;Anal cancer;Arthralgia;Blood creatinine increased;Calculus urinary;Circulatory collapse;Clostridium difficile colitis;Dehydration;Dermatitis allergic;Diarrhoea;Drug withdrawal syndrome;Dyspnoea;Erysipelas;Fatigue;Fluid overload;Gastrointestinal disorder;Gastrointestinal infection;General physical health deterioration;Haemorrhoidal haemorrhage;Headache;Hepatic encephalopathy;Hepatic failure;Hepatobiliary disease;Hepatocellular carcinoma;Hypersensitivity vasculitis;Hypertension;Hyponatraemia;Infection;Lactic acidosis;Liver disorder;Lymphoedema;Mental disorder;Myocardial infarction;Nausea;Neoplasm;Neutropenia;Pancreatitis acute;Pancytopenia;Peritonitis bacterial;Portal vein thrombosis;Sleep disorder;Soft tissue infection;Somnolence;Streptococcal sepsis;Vertigo,1130780113,OT,,,,,,,,,1130780113,1,Chronic hepatitis C
11630606,116306062,2,F,,20170725,20151014,20170731,EXP,,CA-ABBVIE-15K-028-1478419-00,ABBVIE,,32,YR,,M,Y,53,KG,20170731,,OT,CA,CA,EFAVIRENZ,Depression;Drug interaction,116306062,OT,,,,,,,,,116306062,1,Product used for unknown indication
11910157,119101572,2,F,2013,20170727,20160112,20170811,EXP,,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2015R1-109170,RANBAXY,"BRAHMACHARI U, SAHA S, GUCHHAIT B, GUHA SK. DISSEMINATED MYCOBACTERIUM SIMIAE MANIFESTED AS IRIS: A CASE REPORT. HIV AIDS REV. 2015;14(3):93-95",32,YR,,F,Y,,,20170811,,OT,IN,IN,Efavirenz,Bone marrow failure;Death;Drug ineffective;Escherichia urinary tract infection;Immune reconstitution inflammatory syndrome;Mycobacterial infection;Pancytopenia;Pulmonary tuberculosis,119101572,OT,,,119101572,1,20130414,2013,,,119101572,1,HIV infection
11937618,119376186,6,F,,20170905,20160122,20170915,EXP,,CA-009507513-1601CAN007640,MERCK,,,,,M,Y,,,20170915,,CN,US,CA,SUSTIVA,Depression;Drug interaction,119376186,OT,,,,,,,,,119376186,1,Product used for unknown indication
12185435,121854353,3,F,20160123,20170811,20160316,20170821,EXP,,PT-BMSGILMSD-2016-0203290,GILEAD,,46,YR,A,M,Y,,,20170821,,MD,PT,PT,EFAVIRENZ,Arrhythmia;Cardiac failure,121854353,HO,,,121854353,1,20150825,20160126,,,121854353,1,Hepatitis C
12542248,125422482,2,F,20040331,20170920,20160708,20170929,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-055352,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20170929,,MD,JP,JP,EFAVIRENZ,Hyperlipidaemia;Lipodystrophy acquired;Liver disorder,125422482,OT,,,125422482,1,20000613,20010814,,,125422482,1,HIV infection
12607822,126078223,3,F,20160531,20170712,20160729,20170718,EXP,,AM-JNJFOC-20160723655,JANSSEN,,43,YR,A,M,Y,,,20170718,,MD,AM,AM,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Acute kidney injury;Anal incontinence;Condition aggravated;Depressed level of consciousness;Dyspnoea at rest;Fatigue;HIV infection;Hypoalbuminaemia;Treatment noncompliance;Tuberculosis;Urinary incontinence,126078223,OT,,,126078223,1,20140620,20140621,,,126078223,1,Tuberculosis
12689615,1268961515,15,F,20160812,20170923,20160826,20170928,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2016GSK123261,VIIV,,37,YR,,F,Y,43,KG,20170928,,MD,BR,BR,EFAVIRENZ,Acute kidney injury;Immune reconstitution inflammatory syndrome,1268961515,LT,,,1268961515,1,20160805,,,,1268961515,1,HIV infection
12836982,128369822,2,F,20160818,20170724,20161011,20170803,EXP,,BR-MYLANLABS-2016M1043230,MYLAN,,,,,,Y,,,20170802,,CN,US,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal distress syndrome;Foetal exposure during pregnancy;Stillbirth,128369822,DE,,,,,,,,,128369822,1,Product used for unknown indication
12953694,129536944,4,F,20161109,20170721,20161117,20170728,EXP,,ZW-GILEAD-2016-0243462,GILEAD,,36,YR,A,M,Y,77.5,KG,20170728,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma;Sepsis,129536944,HO,,,129536944,1,20150423,20161109,,,129536944,1,Kaposi's sarcoma AIDS related
12996569,129965696,6,F,201612,20170713,20161204,20170718,EXP,,CA-GLAXOSMITHKLINE-CA2016GSK157626,GLAXOSMITHKLINE,,49,YR,,M,Y,,,20170718,,CN,CA,CA,Efavirenz,Aphonia;Dysphonia;Eczema;Hepatitis B;Intervertebral disc protrusion;Lumbar spinal stenosis;Nasopharyngitis;Nausea;Pulmonary pain;Sleep disorder;Syphilis,129965696,OT,,,129965696,2,20161025,20170120,,,129965696,1,Product used for unknown indication
13109551,131095514,4,F,20160922,20170816,20170112,20170825,EXP,,BR-GILEAD-2017-0252446,GILEAD,,36,YR,A,M,Y,113.3,KG,20170825,,MD,BR,BR,EFAVIRENZ,Anal abscess;Rectal haemorrhage,131095514,HO,,,131095514,1,20150505,,,,131095514,1,HIV infection
13111155,131111555,5,F,201612,20170713,20170112,20170718,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2016GSK157626,VIIV,,49,YR,,M,Y,,,20170718,,CN,CA,CA,Efavirenz,Aphonia;Dysphonia;Eczema;Hepatitis B;Intervertebral disc protrusion;Lumbar spinal stenosis;Nasopharyngitis;Nausea;Pulmonary pain;Sleep disorder;Syphilis,131111555,OT,,,131111555,2,20161025,20170120,,,131111555,1,Product used for unknown indication
13144218,1314421810,10,F,20170116,20170823,20170124,20170828,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-004480,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170828,,CN,BR,BR,EFAVIRENZ,Atrial septal defect;Cardiomegaly;Cerebral calcification;Cerebral cyst;Cerebral ventricle dilatation;Congenital central nervous system anomaly;Congenital cytomegalovirus infection;Dandy-Walker syndrome;Foetal cardiac disorder;Foetal exposure during pregnancy;Foetal growth restriction;HIV infection;Haemoglobin decreased;Microcephaly;Platelet count decreased;Platelet transfusion;Pneumonia cytomegaloviral;Premature baby;Skull malformation;Transfusion,1314421810,HO,,,1314421810,1,20161223,20170201,,,1314421810,1,Prophylaxis against HIV infection
13195465,131954656,6,F,20170201,20170823,20170208,20170828,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-010413,BRISTOL MYERS SQUIBB,,15,YR,,F,Y,62,KG,20170828,,CN,BR,BR,EFAVIRENZ,Caesarean section;Folliculitis;Maternal exposure during pregnancy;Premature delivery,131954656,OT,,,131954656,1,20161223,20170201,,,131954656,1,HIV infection
13214799,132147992,2,F,,20170720,20170210,20170721,EXP,,CN-PFIZER INC-2017056653,PFIZER,"ZUO, S.. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAKISTAN JOURNAL OF MEDICAL SCIENCES. 2016;32 (6):1574-1579",28,YR,,M,Y,,,20170721,,MD,CN,CN,EFAVIRENZ,Bone marrow failure;Sepsis,132147992,OT,,,,,,,,,132147992,1,Non-Hodgkin's lymphoma
13220170,132201705,5,F,20170201,20170705,20170210,20170719,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-010253,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,1.89,KG,20170719,,OT,BR,BR,EFAVIRENZ,Atrial septal defect;Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,132201705,CA,,,132201705,1,20161223,20170201,,,132201705,1,Prophylaxis against HIV infection
13231333,132313337,7,F,20170206,20170823,20170214,20170825,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-011471,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170825,,OT,BR,BR,EFAVIRENZ,Ankyloglossia congenital;Bradycardia neonatal;Foetal distress syndrome;Foetal exposure during pregnancy;Meconium abnormal;Neonatal respiratory depression;Strabismus congenital,132313337,HO,,,132313337,1,20161021,20170205,,,132313337,1,Product used for unknown indication
13303645,133036452,2,F,20170301,20170706,20170307,20170720,EXP,,ZW-GILEAD-2017-0261170,GILEAD,,54,YR,A,M,Y,65.7,KG,20170720,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,133036452,HO,,,133036452,1,20140701,20160622,,,133036452,1,Kaposi's sarcoma AIDS related
13360010,133600102,2,F,20170126,20170803,20170322,20170809,EXP,,CD-JNJFOC-20170317513,JANSSEN,,40,YR,A,F,Y,,,20170809,,OT,CD,CD,EFAVIRENZ,Abdominal distension;Abdominal pain;Anaemia;Hypovolaemic shock;Psychotic disorder;Respiratory disorder;Sepsis,133600102,DE,,,133600102,2,20161207,,,,133600102,1,Tuberculosis
13360371,133603712,2,F,20170125,20170803,20170322,20170809,EXP,,CD-JNJFOC-20170317491,JANSSEN,,48,YR,A,F,Y,,,20170809,,OT,CD,CD,EFAVIRENZ,Asthenia;Candida infection;Diarrhoea;Electrolyte imbalance;Genital ulceration;Hypotension;Melaena;Oedema peripheral;Oral herpes;Swelling face;Vertigo;Vomiting,133603712,DE,,,133603712,1,20161228,,,,133603712,1,Tuberculosis
13484467,134844679,9,F,20161215,20170920,20170425,20170925,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-033775,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170925,,MD,BR,BR,EFAVIRENZ,Congenital tricuspid valve incompetence;Foetal exposure during pregnancy,134844679,CA,,,134844679,1,20161118,20170325,,,134844679,1,Prophylaxis against HIV infection
13509692,135096922,2,F,20170203,20170516,20170503,20170803,PER,,US-SA-2017SA032939,AVENTIS,,,,A,F,Y,,,20170803,,PH,US,US,EFAVIRENZ,CD4 lymphocytes decreased,,,,,135096922,1,20170201,20170215,,,,,
13535187,135351872,2,F,201702,20170607,20170511,20170810,PER,,US-VIFOR (INTERNATIONAL) INC.-VIT-2017-02029,VIFOR,,29,YR,,M,Y,,,20170810,,PH,US,US,SUSTIVA,Constipation;Diarrhoea;Flatulence;Peripheral swelling;Swelling face,,,,,135351872,1,201702,201702,,,135351872,1,Hyperkalaemia
13546643,135466433,3,F,20170418,20170711,20170515,20170720,EXP,,GB-GILEAD-2017-0272377,GILEAD,,53,YR,A,F,Y,66,KG,20170720,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Peripheral ischaemia,135466433,HO,,,135466433,1,20100617,,,,135466433,1,HIV infection
13591958,135919584,4,F,20170514,20170719,20170530,20170724,EXP,,LS-JNJFOC-20170521517,JANSSEN,,45,YR,A,F,Y,47,KG,20170724,,MD,LS,LS,EFAVIRENZ,AIDS related complication;Drug interaction;Gastroenteritis;Sudden death,135919584,DE,,,135919584,1,20161231,20170519,,,135919584,1,Tuberculosis
13608714,136087148,8,F,20170513,20170722,20170602,20170726,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-048141,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,2.49,KG,20170726,,OT,BR,BR,EFAVIRENZ,Foetal exposure during pregnancy;Poor sucking reflex;Premature baby;Transient tachypnoea of the newborn,136087148,LT,,,136087148,1,20170329,,,,136087148,1,Prophylaxis against HIV infection
13610646,136106466,6,F,20170513,20170704,20170605,20170707,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK082929,VIIV,,0,DY,,M,Y,2.94,KG,20170707,,MD,BR,BR,Efavirenz,Premature baby,136106466,HO,,,136106466,1,20170329,20170512,,,136106466,1,HIV infection
13631960,136319603,3,F,20170525,20170814,20170608,20170822,EXP,,KE-GILEAD-2017-0276578,GILEAD,,33,YR,A,M,Y,,,20170822,,OT,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury,136319603,OT,,,136319603,1,20170227,20170524,,,136319603,1,Kaposi's sarcoma AIDS related
13640921,136409213,3,F,20170530,20170714,20170612,20170719,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-050474,BRISTOL MYERS SQUIBB,,20,YR,,F,Y,62,KG,20170719,,OT,BR,BR,EFAVIRENZ,Caesarean section;Cephalo-pelvic disproportion;Genital herpes;Iron deficiency anaemia;Live birth;Maternal exposure during pregnancy;Meconium in amniotic fluid,136409213,OT,,,136409213,1,20170223,,,,136409213,1,HIV infection
13667984,136679848,8,F,20170602,20170817,20170620,20170821,EXP,,TZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-052405,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,85,KG,20170821,,OT,TZ,TZ,EFAVIRENZ,Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,136679848,HO,,,136679848,1,20170313,,,,136679848,1,HIV infection
13675730,136757302,2,F,20170518,20170706,20170621,20170713,EXP,,ZA-GILEAD-2017-0278617,GILEAD,,29,YR,A,M,Y,82.2,KG,20170713,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Suicide attempt,136757302,LT,,,136757302,1,20150605,201705,,,136757302,1,HIV infection
13680733,136807333,3,F,20170513,20170722,20170623,20170726,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-053522,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170726,,OT,BR,BR,EFAVIRENZ,Anaemia;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,136807333,OT,,,136807333,1,20170329,,,,136807333,1,HIV infection
13684980,136849804,4,F,20170608,20170726,20170623,20170814,EXP,,KE-GILEAD-2017-0279230,GILEAD,,53,YR,A,M,Y,56.4,KG,20170814,,MD,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,136849804,OT,,,136849804,1,20170322,20170511,,,136849804,1,Acquired immunodeficiency syndrome
13684981,136849812,2,F,20170608,20170706,20170623,20170719,EXP,,ZW-GILEAD-2017-0279194,GILEAD,,39,YR,A,M,Y,64,KG,20170719,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,136849812,HO,,,136849812,1,20161129,20170315,,,136849812,1,Kaposi's sarcoma AIDS related
13685470,136854702,2,F,,20170720,20170623,20170728,EXP,,ES-GILEAD-2017-0278162,GILEAD,,64,YR,A,F,Y,,,20170728,,MD,ES,ES,EFAVIRENZ,Osteopenia;Osteoporosis,136854702,OT,,,136854702,1,201010,,,,136854702,1,HIV infection
13686825,136868257,7,F,20170604,20170817,20170623,20170821,EXP,,TZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-052094,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.2,KG,20170821,,OT,TZ,TZ,EFAVIRENZ,Anaemia;Exposure during breast feeding;Foetal exposure during pregnancy;Necrotising colitis;Platelet count decreased;Premature baby;Sepsis neonatal;White blood cell count decreased,136868257,DE,,,136868257,1,20170313,20170604,,,136868257,1,Prophylaxis against HIV infection
13690675,136906752,2,F,200705,20170824,20170626,20170829,EXP,,SE-GLAXOSMITHKLINE-SE2017GSK097135,GLAXOSMITHKLINE,,59,YR,,M,Y,70,KG,20170829,,CN,SE,SE,EFAVIRENZ,Abnormal behaviour;Amnesia;CD4 lymphocytes decreased;Confusional state;Cough;Disorientation;Headache;Loss of consciousness;Loss of personal independence in daily activities;Meningoencephalitis viral;Restlessness,136906752,HO,,,,,,,,,136906752,1,Product used for unknown indication
13695444,136954442,2,F,201705,20170824,20170627,20170831,EXP,,PHHY2017SE094220,NOVARTIS,,69,YR,,M,Y,70,KG,20170831,,CN,US,SE,EFAVIRENZ,Abnormal behaviour;Amnesia;CD4 lymphocytes decreased;Confusional state;Cough;Disorientation;Headache;Loss of consciousness;Loss of personal independence in daily activities;Meningoencephalitis viral;Restlessness,136954442,HO,,,,,,,,,136954442,1,Product used for unknown indication
13697384,136973842,2,F,,20170623,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099689,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",48,YR,,F,Y,,,20170705,,MD,IN,IN,EFAVIRENZ,Anaemia;Drug reaction with eosinophilia and systemic symptoms;Oral disorder;Rash;Rash maculo-papular;Vomiting,136973842,HO,,,,,,,,,136973842,1,Antiretroviral therapy
13697385,136973852,2,F,,20170623,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099692,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",32,YR,,M,Y,,,20170705,,MD,IN,IN,EFAVIRENZ,Rash maculo-papular,136973852,OT,,,,,,,,,136973852,1,Antiretroviral therapy
13697386,136973862,2,F,,20170623,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099687,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",35,YR,,F,Y,,,20170705,,MD,IN,IN,EFAVIRENZ,Oral disorder;Rash maculo-papular,136973862,OT,,,,,,,,,136973862,1,Antiretroviral therapy
13697389,136973892,2,F,,20170623,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099688,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",36,YR,,F,Y,,,20170705,,MD,IN,IN,EFAVIRENZ,Asthma;Condition aggravated;Dermatitis atopic;Rash maculo-papular,136973892,OT,,,,,,,,,136973892,1,Antiretroviral therapy
13697391,136973912,2,F,,20170623,20170628,20170705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2017099685,VIIV,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",39,YR,,F,Y,,,20170705,,MD,IN,IN,EFAVIRENZ,Hepatic enzyme increased;Rash maculo-papular,136973912,OT,,,,,,,,,136973912,1,Antiretroviral therapy
13697503,136975032,2,F,,20170623,20170628,20170705,EXP,,IN-GLAXOSMITHKLINE-IN2017099689,GLAXOSMITHKLINE,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",48,YR,,F,Y,,,20170705,,MD,IN,IN,EFAVIRENZ,Anaemia;Drug reaction with eosinophilia and systemic symptoms;Oral disorder;Rash;Rash maculo-papular;Vomiting,136975032,HO,,,,,,,,,136975032,1,Antiretroviral therapy
13697505,136975052,2,F,,20170623,20170628,20170705,EXP,,IN-GLAXOSMITHKLINE-IN2017099687,GLAXOSMITHKLINE,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",35,YR,,F,Y,,,20170705,,MD,IN,IN,EFAVIRENZ,Oral disorder;Rash maculo-papular,136975052,OT,,,,,,,,,136975052,1,Antiretroviral therapy
13697510,136975102,2,F,,20170623,20170628,20170705,EXP,,IN-GLAXOSMITHKLINE-IN2017099688,GLAXOSMITHKLINE,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",36,YR,,F,Y,,,20170705,,MD,IN,IN,EFAVIRENZ,Asthma;Condition aggravated;Dermatitis atopic;Rash maculo-papular,136975102,OT,,,,,,,,,136975102,1,Antiretroviral therapy
13697512,136975122,2,F,,20170623,20170628,20170705,EXP,,IN-GLAXOSMITHKLINE-IN2017099685,GLAXOSMITHKLINE,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTIRETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN JOURNAL OF DERMATOLOGY, VENEREOLOGY, AND LEPROLOGY. 2017;83(4):502-504",39,YR,,F,Y,,,20170705,,MD,IN,IN,EFAVIRENZ,Hepatic enzyme increased;Rash maculo-papular,136975122,OT,,,,,,,,,136975122,1,Antiretroviral therapy
13711561,137115611,1,I,20170423,20170626,20170703,20170703,EXP,,FR-GILEAD-2017-0281042,GILEAD,,27,YR,A,M,Y,,,20170703,,OT,FR,FR,EFAVIRENZ MYLAN,Bicytopenia;Hepatitis;Off label use;Pyrexia;Vertigo,137115611,OT,,,137115611,1,20170423,20170511,,,137115611,1,Exposure to body fluid
13712779,137127792,2,F,201309,20170707,20170703,20170717,EXP,,DE-GILEAD-2017-0280889,GILEAD,,34,YR,A,M,Y,66.5,KG,20170717,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Acute hepatitis C;Burkitt's lymphoma;Hepatic mass;Splenomegaly,137127792,HO,,,137127792,1,2009,,,,137127792,1,HIV infection
13713354,137133541,1,I,,20161202,20170704,20170704,PER,,JP-LUPIN PHARMACEUTICALS INC.-2016-05492,LUPIN,,44,YR,,M,Y,,,20170704,,OT,JP,JP,EFAVIRENZ,Nightmare,,,,,,,,,,,137133541,1,HIV infection
13713654,137136542,2,F,,20170619,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-059185,BRISTOL MYERS SQUIBB,,25,YR,,M,Y,,,20170804,,OT,DE,ET,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,137136542,OT,,,,,,,,,137136542,1,HIV infection
13713693,137136932,2,F,,20170719,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-058794,BRISTOL MYERS SQUIBB,,51,YR,,M,Y,,,20170804,,OT,DE,ET,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,137136932,OT,,,,,,,,,137136932,1,HIV infection
13713694,137136942,2,F,,20170619,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-059182,BRISTOL MYERS SQUIBB,,28,YR,,M,Y,,,20170804,,OT,DE,ET,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,137136942,OT,,,,,,,,,137136942,1,HIV infection
13713829,137138292,2,F,,20170619,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-059183,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20170804,,OT,DE,ET,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,137138292,OT,,,,,,,,,137138292,1,HIV infection
13713839,137138392,2,F,,20170619,20170704,20170804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-059186,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20170804,,OT,DE,ET,EFAVIRENZ,Viral mutation identified;Virologic failure,137138392,OT,,,,,,,,,137138392,1,HIV infection
13716882,137168821,1,I,2017,20170630,20170705,20170705,EXP,,LS-JNJFOC-20170700531,JANSSEN,,38,YR,A,M,Y,54,KG,20170705,,MD,LS,LS,EFAVIRENZ,Cardiac failure congestive;Electrocardiogram QT prolonged;Pulmonary oedema;Respiratory failure,137168821,HO,,,137168821,1,20170112,20170626,,,137168821,1,Tuberculosis
13717296,137172961,1,I,20170423,20170626,20170705,20170705,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017102472,VIIV,,27,YR,,M,Y,,,20170705,,CN,FR,FR,EFAVIRENZ,Bicytopenia;Hepatitis;Off label use;Pyrexia;Vertigo,137172961,OT,,,137172961,1,20170423,20170511,,,137172961,1,Exposure to body fluid
13717445,137174451,1,I,20170423,20170626,20170705,20170705,EXP,,FR-GLAXOSMITHKLINE-FR2017102472,GLAXOSMITHKLINE,,27,YR,,M,Y,,,20170705,,CN,FR,FR,EFAVIRENZ,Bicytopenia;Hepatitis;Off label use;Pyrexia;Vertigo,137174451,HO,,,137174451,1,20170423,20170511,,,137174451,1,Exposure to body fluid
13718110,137181103,3,F,2014,20170817,20170705,20170823,PER,,US-GILEAD-2017-0281053,GILEAD,,54,YR,A,M,Y,96.6,KG,20170823,,PH,US,US,SUSTIVA,Amnesia;Drug dose omission;Insurance issue;Memory impairment,,,,,137181103,1,20160408,20160609,,,137181103,1,HIV infection
13725012,137250121,1,I,,20031204,20170706,20170706,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12454591,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170706,,CN,FR,SN,EFAVIRENZ,Cervix carcinoma stage 0,137250121,HO,,,,,,,,,137250121,1,HIV infection
13726052,137260521,1,I,,20170316,20170707,20170707,PER,,US-DRREDDYS-USA/USA/17/0088042,DR REDDYS,"MULANOVICH V, DESAI P, POPAT U. ALLOGENEIC STEM CELL TRANSPLANTATION FOR HIV-POSITIVE PATIENTS WITH HEMATOLOGIC MALIGNANCIES. AIDS. 2016;30(17):2653-7.",38,YR,,M,Y,,,20170707,,MD,COUNTRY NOT SPECIFIED,US,efavirenz,Acute kidney injury;Dehydration;Hyperkalaemia;Nausea;Vomiting,137260521,OT,,,,,,,,,137260521,1,Immunosuppression
13726632,137266321,1,I,,20170629,20170706,20170706,EXP,,US-GILEAD-2017-0281750,GILEAD,,,,,M,Y,,,20170706,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nephrolithiasis,137266321,OT,,,,,,,,,137266321,1,HIV infection
13736498,137364981,1,I,20170621,20170621,20170710,20170710,EXP,,MX-VIIV HEALTHCARE LIMITED-MX2017GSK098190,VIIV,,31,YR,,M,Y,68,KG,20170710,,MD,MX,MX,EFAVIRENZ,Pancreatitis,137364981,DE,,,137364981,1,20170619,20170621,,,137364981,1,HIV infection
13739482,137394821,1,I,20170608,,20170710,20170710,DIR,FDA-CDER-CTU-2017-42825,,FDA-CTU,,53,YR,,M,N,56.4,KG,20170629,Y,OT,US,US,EFAVIRENZ AND EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Blood albumin decreased;Blood phosphorus decreased;Blood sodium decreased;CD4 lymphocytes decreased;Neutrophil count decreased;Platelet count decreased;Treatment noncompliance,137394821,OT,137394821,HP,137394821,1,20170322,20170511,,,137394821,1,Kaposi's sarcoma
13739571,137395711,1,I,,20170705,20170711,20170711,EXP,,BF-GLAXOSMITHKLINE-BF2017106243,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170711,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Virologic failure,137395711,OT,,,,,,,,,137395711,1,Prophylaxis against HIV infection
13739573,137395731,1,I,,20170705,20170711,20170711,EXP,,BF-GLAXOSMITHKLINE-BF2017106240,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANSEGUIN-DEVAUX DOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170711,,OT,BF,BF,EFAVIRENZ,Exposure during breast feeding;Viral mutation identified;Virologic failure,137395731,OT,,,,,,,,,137395731,1,Prophylaxis against HIV infection
13739816,137398161,1,I,,20170705,20170711,20170711,EXP,,BF-GLAXOSMITHKLINE-BF2017106244,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170711,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Virologic failure,137398161,OT,,,,,,,,,137398161,1,Prophylaxis against HIV infection
13739841,137398411,1,I,,20170705,20170711,20170711,EXP,,BF-GLAXOSMITHKLINE-BF2017106246,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170711,,OT,BF,BF,EFAVIRENZ,Exposure during breast feeding;Viral mutation identified;Virologic failure,137398411,OT,,,,,,,,,137398411,1,Prophylaxis against HIV infection
13740546,137405461,1,I,,20170515,20170711,20170711,PER,,MY-LUPIN PHARMACEUTICALS INC.-2017-02631,LUPIN,,43,YR,,F,Y,,,20170710,,OT,MY,MY,EFAVIRENZ,Myalgia;Pyrexia;Rash maculo-papular;Rash pruritic,137405461,HO,,,,,,,,,137405461,1,Antiretroviral therapy
13743093,137430931,1,I,201201,20130225,20170711,20170711,EXP,,PHHY2013FR023865,NOVARTIS,,71,YR,,F,Y,,,20170711,,OT,FR,FR,SUSTIVA,Cardiac septal hypertrophy;Cardiac valve disease;Hypertrophic cardiomyopathy,137430931,HO,,,,,,,,,137430931,1,Age-related macular degeneration
13743205,137432051,1,I,,20170628,20170711,20170711,EXP,,PHHY2017US098959,SANDOZ,,32,YR,,M,Y,,,20170711,,OT,US,US,EFAVIRENZ,Drug interaction;Gynaecomastia,137432051,OT,,,,,,,,,137432051,1,Pulmonary tuberculosis
13743208,137432081,1,I,,20170628,20170711,20170711,EXP,,PHHY2017US099563,SANDOZ,,68,YR,,M,Y,,,20170711,,OT,US,US,EFAVIRENZ,Drug interaction;Dysuria;Gynaecomastia;Prostatitis,137432081,OT,,,,,,,,,137432081,1,Pulmonary tuberculosis
13743642,137436421,1,I,20160411,20170626,20170711,20170711,EXP,,GB-GILEAD-2017-0280691,GILEAD,,53,YR,A,M,Y,,,20170711,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cholecystitis acute,137436421,OT,,,,,,,,,137436421,1,HIV infection
13746944,137469441,1,I,,20170629,20170712,20170712,EXP,,PHHY2017DE097218,SANDOZ,,43,YR,,M,Y,,,20170712,,OT,DE,DE,EFAVIRENZ,Acute kidney injury;Back pain;Metabolic acidosis;Nausea;Overdose;Vomiting,137469441,HO,,,,,,,,,137469441,1,Analgesic therapy
13747003,137470031,1,I,,20170705,20170712,20170712,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106240,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANSEGUIN-DEVAUX DOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712,,OT,BF,BF,EFAVIRENZ,Exposure during breast feeding;Viral mutation identified;Virologic failure,137470031,OT,,,,,,,,,137470031,1,Prophylaxis against HIV infection
13747085,137470851,1,I,,20170705,20170712,20170712,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106243,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Virologic failure,137470851,OT,,,,,,,,,137470851,1,Prophylaxis against HIV infection
13747127,137471271,1,I,,20170705,20170712,20170712,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106244,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Virologic failure,137471271,OT,,,,,,,,,137471271,1,Prophylaxis against HIV infection
13747503,137475031,1,I,,20170705,20170712,20170712,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106247,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Viral mutation identified;Virologic failure,137475031,OT,,,,,,,,,137475031,1,Prophylaxis against HIV infection
13747504,137475041,1,I,,20170705,20170712,20170712,EXP,,BF-GLAXOSMITHKLINE-BF2017106247,GLAXOSMITHKLINE,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170712,,OT,BF,BF,EFAVIRENZ,Foetal exposure during pregnancy;Viral mutation identified;Virologic failure,137475041,OT,,,,,,,,,137475041,1,Prophylaxis against HIV infection
13752828,137528281,1,I,20170111,,20170713,20170713,DIR,US-FDA-377832,,FDA-CTU,,61,YR,,M,N,70.8,KG,20170713,N,OT,US,US,EFAVIRENZ,Abnormal dreams,137528281,OT,137528281,HP,137528281,1,,,6,MON,137528281,1,HIV infection
13754304,137543041,1,I,,20170703,20170714,20170714,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017105237,VIIV,"NDOW G, GORE ML, SHIMAKAWA Y, SUSO P, JATTA A, TAMBA S. HEPATITIS B TESTING AND TREATMENT IN HIV PATIENTS IN THE GAMBIA - COMPLIANCE WITH INTERNATIONAL GUIDELINES AND CLINICAL OUTCOMES. PLOS ONE.  2017;12(6)",50,YR,,F,Y,85,KG,20170714,,MD,GB,GB,EFAVIRENZ,Pathogen resistance,137543041,OT,,,,,,,,,137543041,1,Antiretroviral therapy
13754306,137543061,1,I,,20170703,20170714,20170714,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017105236,VIIV,"NDOW G, GORE ML, SHIMAKAWA Y, SUSO P, JATTA A, TAMBA S. HEPATITIS B TESTING AND TREATMENT IN HIV PATIENTS IN THE GAMBIA - COMPLIANCE WITH INTERNATIONAL GUIDELINES AND CLINICAL OUTCOMES. PLOS ONE.  2017;12(6)",42,YR,,F,Y,67,KG,20170714,,MD,GB,GB,EFAVIRENZ,Pathogen resistance,137543061,OT,,,,,,,,,137543061,1,Antiretroviral therapy
13754395,137543951,1,I,,20170703,20170714,20170714,EXP,,GB-GLAXOSMITHKLINE-GB2017105237,GLAXOSMITHKLINE,"NDOW G, GORE ML, SHIMAKAWA Y, SUSO P, JATTA A, TAMBA S. HEPATITIS B TESTING AND TREATMENT IN HIV PATIENTS IN THE GAMBIA - COMPLIANCE WITH INTERNATIONAL GUIDELINES AND CLINICAL OUTCOMES. PLOS ONE.  2017;12(6)",50,YR,,F,Y,85,KG,20170714,,MD,GB,GB,EFAVIRENZ,Pathogen resistance,137543951,OT,,,,,,,,,137543951,1,Antiretroviral therapy
13754396,137543961,1,I,,20170703,20170714,20170714,EXP,,GB-GLAXOSMITHKLINE-GB2017105236,GLAXOSMITHKLINE,"NDOW G, GORE ML, SHIMAKAWA Y, SUSO P, JATTA A, TAMBA S. HEPATITIS B TESTING AND TREATMENT IN HIV PATIENTS IN THE GAMBIA - COMPLIANCE WITH INTERNATIONAL GUIDELINES AND CLINICAL OUTCOMES. PLOS ONE.  2017;12(6)",42,YR,,F,Y,67,KG,20170714,,MD,GB,GB,EFAVIRENZ,Pathogen resistance,137543961,OT,,,,,,,,,137543961,1,Antiretroviral therapy
13755549,137555491,1,I,,20170701,20170714,20170714,EXP,,IN-MYLANLABS-2017M1041666,MYLAN,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTI RETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN-J-DERMATOL-VENEREOL-LEPROL 2017;83(4):502-504.",48,YR,,F,Y,,,20170714,,OT,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Anaemia;Drug reaction with eosinophilia and systemic symptoms;Rash maculo-papular;Vomiting,137555491,OT,,,,,,,,,137555491,1,HIV infection
13755550,137555501,1,I,,20170701,20170714,20170714,EXP,,IN-MYLANLABS-2017M1041830,MYLAN,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTI RETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN-J-DERMATOL-VENEREOL-LEPROL 2017;83(4):502-504.",36,YR,,F,Y,,,20170714,,OT,IN,IN,EFAVIRENZ W/LAMIVUDINE/ZIDOVUDINE,Asthma;Dermatitis atopic,137555501,OT,,,,,,,,,137555501,1,HIV infection
13755735,137557351,1,I,,20170706,20170714,20170714,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-061871,BRISTOL MYERS SQUIBB,,67,YR,,M,Y,,,20170714,,OT,PT,PT,EFAVIRENZ,Progressive multifocal leukoencephalopathy,137557351,HO,,,,,,,,,137557351,1,HIV infection
13756645,137566451,1,I,,20170705,20170714,20170714,EXP,,BF-VIIV HEALTHCARE LIMITED-BF2017106246,VIIV,"DAHOUROU DL, AMORISSANI-FOLQUET M, MALATESTE K, AMANI-BOSSE C, COULIBALY M, SEGUIN-DEVAUX C ET AL. EFAVIRENZ-BASED SIMPLIFICATION AFTER SUCCESSFUL EARLY LOPINAVIR-BOOSTED-RITONAVIR-BASED THERAPY IN HIV-INFECTED CHILDREN IN BURKINA FASO AND C?TE D^IVOIRE: THE MONOD ANRS 12206 NON-INFERIORITY RANDOMISED TRIAL. BMC MEDICINE. 2017;15(1):85.",,,C,,Y,,,20170714,,OT,BF,BF,EFAVIRENZ,Exposure during breast feeding;Viral mutation identified;Virologic failure,137566451,OT,,,,,,,,,137566451,1,Prophylaxis against HIV infection
13760045,137600451,1,I,20170515,20170710,20170717,20170717,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-063543,BRISTOL MYERS SQUIBB,,63,YR,,F,Y,,,20170717,,OT,CN,CN,EFAVIRENZ,Oral herpes;Rash,137600451,HO,,,137600451,1,20170410,,,,137600451,1,HIV infection
13768302,137683021,1,I,,20170711,20170719,20170719,EXP,,AU-PFIZER INC-2017306411,PFIZER,"KOELSCH, K.. IMPACT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ON THE HIV RESERVOIR AND IMMUNE RESPONSE IN 3 HIV-INFECTED INDIVIDUALS. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2017;75 (3):328-337",,,,M,Y,,,20170719,,MD,AU,AU,EFAVIRENZ,Candida infection;Fungaemia,137683021,OT,,,137683021,1,201207,,,,137683021,1,Acute myeloid leukaemia
13769936,137699361,1,I,,20170711,20170719,20170719,EXP,,TH-GLAXOSMITHKLINE-TH2017109349,GLAXOSMITHKLINE,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89-96",,,,,Y,,,20170719,,OT,TH,TH,EFAVIRENZ,Cervical dysplasia,137699361,HO,,,,,,,,,137699361,1,HIV infection
13769939,137699391,1,I,,20170711,20170719,20170719,EXP,,TH-GLAXOSMITHKLINE-TH2017109352,GLAXOSMITHKLINE,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89-96",,,,,Y,,,20170719,,OT,TH,TH,EFAVIRENZ,Endocarditis enterococcal,137699391,OT,,,,,,,,,137699391,1,HIV infection
13769942,137699421,1,I,,20170711,20170719,20170719,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2017109349,VIIV,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89-96",,,,,Y,,,20170719,,OT,TH,TH,EFAVIRENZ,Cervical dysplasia,137699421,OT,,,,,,,,,137699421,1,HIV infection
13769946,137699461,1,I,,20170711,20170719,20170719,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2017109352,VIIV,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89-96",,,,,Y,,,20170719,,OT,TH,TH,EFAVIRENZ,Endocarditis enterococcal,137699461,HO,,,,,,,,,137699461,1,HIV infection
13770384,137703841,1,I,,20170713,20170719,20170719,PER,,US-GILEAD-2017-0283423,GILEAD,,,,,F,Y,,,20170719,,MD,US,US,SUSTIVA,Joint swelling,,,,,,,,,,,137703841,1,Product used for unknown indication
13776722,137767221,1,I,,20170714,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111893,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Virologic failure,137767221,OT,,,,,,,,,137767221,1,HIV infection
13776726,137767261,1,I,,20170714,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111888,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767261,OT,,,,,,,,,137767261,1,HIV infection
13776729,137767291,1,I,,20170714,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111890,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767291,OT,,,,,,,,,137767291,1,HIV infection
13776734,137767341,1,I,,20170714,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111892,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767341,OT,,,,,,,,,137767341,1,HIV infection
13776737,137767371,1,I,,20170714,20170720,20170720,EXP,,TZ-VIIV HEALTHCARE LIMITED-TZ2017111889,VIIV,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767371,OT,,,,,,,,,137767371,1,HIV infection
13776748,137767481,1,I,,20170714,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111889,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767481,OT,,,,,,,,,137767481,1,HIV infection
13776750,137767501,1,I,,20170714,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111893,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Virologic failure,137767501,OT,,,,,,,,,137767501,1,HIV infection
13776752,137767521,1,I,,20170714,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111888,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767521,OT,,,,,,,,,137767521,1,HIV infection
13776757,137767571,1,I,,20170714,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111890,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767571,OT,,,,,,,,,137767571,1,HIV infection
13776759,137767591,1,I,,20170714,20170720,20170720,EXP,,TZ-GLAXOSMITHKLINE-TZ2017111892,GLAXOSMITHKLINE,"NTAMATUNGIRO AJ, MURI L, GLASS TR, ERB S, BATTEGAY M, FURRER H.ET.AL. STRENGTHENING HIV THERAPY AND CARE IN RURAL TANZANIA AFFECTS RATES OF VIRAL SUPPRESSION. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(7):2069-2074",,,A,,Y,,,20170720,,OT,TZ,TZ,EFAVIRENZ,Genotype drug resistance test positive;Virologic failure,137767591,OT,,,,,,,,,137767591,1,HIV infection
13776794,137767942,2,F,,20170728,20170721,20170801,EXP,,PT-GILEAD-2017-0284206,GILEAD,,38,YR,A,F,Y,,,20170801,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,137767942,OT,,,137767942,1,201009,201210,,,137767942,1,HIV infection
13777053,137770531,1,I,20161007,20170713,20170721,20170721,EXP,,FR-GILEAD-2017-0283883,GILEAD,,,,,,Y,,,20170721,,OT,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Ventricular septal defect,137770531,CA,,,137770531,1,20161007,20161007,,,137770531,1,HIV infection
13777727,137777275,5,F,20170706,20170809,20170721,20170814,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-064934,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170814,,OT,BR,BR,EFAVIRENZ,Congenital pyelocaliectasis;Foetal exposure during pregnancy;Foetal macrosomia;Gastrointestinal disorder,137777275,HO,,,137777275,1,20170417,20170706,,,137777275,1,Product used for unknown indication
13778006,137780065,5,F,20170417,20170809,20170721,20170814,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-064616,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,76,KG,20170814,,OT,BR,BR,EFAVIRENZ,Blood pressure increased;Live birth;Maternal exposure during pregnancy;Polyhydramnios;Proteinuria,137780065,HO,,,137780065,1,20170417,,,,137780065,1,HIV infection
13778580,137785801,1,I,20170201,20170713,20170721,20170721,EXP,GB-MHRA-EYC 00161661,GB-GILEAD-2017-0283467,GILEAD,,63,YR,A,M,Y,111,KG,20170721,,PH,GB,GB,EFAVIRENZ,Myalgia,137785801,OT,,,137785801,1,20170110,20170412,,,137785801,1,HIV infection
13779366,137793661,1,I,,20170713,20170721,20170721,PER,,US-GILEAD-2017-0283426,GILEAD,,,,,F,Y,,,20170721,,MD,US,US,SUSTIVA,Off label use,,,,,,,,,,,137793661,1,Product used for unknown indication
13782871,137828711,1,I,20170520,20170531,20170724,20170724,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2017-16618",REGENERON,,,,,,Y,,,20170724,,MD,US,US,SUSTIVA,Myocardial infarction;Pneumonia,137828711,OT,,,137828711,1,20160921,,,,137828711,1,Diabetic retinal oedema
13783297,137832971,1,I,,20170717,20170724,20170724,EXP,,US-GILEAD-2017-0284589,GILEAD,"ASSAD DS, TAHA W. SAFETY AND EFFICACY OF DENOSUMAB IN AN HIV-INFECTED PATIENT WITH OSTEOPOROSIS. ENDOCRINE REVIEWS. CONFERENCE:99TH ANNUAL MEETING OF THE ENDOCRINE SOCIETY, ENDO. 2017;38:UNKNOWN",73,YR,E,F,Y,,,20170724,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Osteoporosis,137832971,OT,,,,,,,,,137832971,1,HIV infection
13783683,137836832,2,F,201707,20170719,20170724,20170801,EXP,,BR-MYLANLABS-2017M1043748,MYLAN,,,,,,Y,,,20170801,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Maternal drugs affecting foetus;Umbilical hernia,137836832,OT,,,137836832,1,20161214,20170705,,,137836832,1,Product used for unknown indication
13787308,137873081,1,I,,20170711,20170725,20170725,EXP,,BR-HETERO LABS LTD-2023710,HETERO,,9,MON,,F,Y,6.32,KG,20170725,,OT,BR,BR,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Congenital umbilical hernia;Exposure during pregnancy,137873081,OT,,,137873081,1,20161214,,,,137873081,1,Product used for unknown indication
13788179,137881792,2,F,,20170710,20170725,20170725,EXP,,BR-CIPLA LTD.-2017BR13216,CIPLA,,,,,,Y,,,20170725,,OT,BR,BR,Efavirenz,Foetal exposure during pregnancy;Umbilical hernia,137881792,CA,,,,,,,,,,,
13791382,137913821,1,I,20170608,20170718,20170725,20170725,EXP,,US-TEVA-790879USA,TEVA,,30,YR,,F,Y,50,KG,20170725,,MD,US,US,EFAVIRENZ,Hypokalaemia,137913821,HO,,,137913821,1,20160217,20170211,,,137913821,1,Product used for unknown indication
13794236,137942361,1,I,,20170313,20170726,20170726,PER,,US-STRIDES ARCOLAB LIMITED-2017SP004621,STRIDES,"FORBES RC, DEMERS A, CONCEPCION BP, MOORE DR, SCHAEFER HM, SHAFFER D.. A2 TO B BLOOD TYPE INCOMPATIBLE DECEASED DONOR KIDNEY TRANSPLANTATION IN A RECIPIENT INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT.. TRANSPLANT-PROC. 2017;49(1):206-209",,,,,Y,,,20170726,,OT,US,US,EFAVIRENZ,Gastrointestinal disorder,,,,,,,,,,,137942361,1,Renal transplant
13794761,137947611,1,I,,20170718,20170726,20170726,EXP,,KE-JNJFOC-20170714103,JOHNSON AND JOHNSON,"IRUNGU K, NYAMU D, OPANGA S. CHARACTERIZATION OF STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS AMONG PATIENTS ADMITTED TO KENYATTA NATIONAL HOSPITAL: A RETROSPECTIVE CROSS-SECTIONAL STUDY. DRUGS REAL WORLD OUTCOMES 2017;4 (2):79-85.",,,,,Y,,,20170726,,OT,KE,KE,EFAVIRENZ,Stevens-Johnson syndrome;Toxic epidermal necrolysis,137947611,HO,,,,,,,,,137947611,2,Product used for unknown indication
13795319,137953191,1,I,,20170718,20170726,20170726,EXP,,BR-STRIDES ARCOLAB LIMITED-2017SP011037,STRIDES,,,,,,Y,,,20170726,,OT,BR,BR,EFAVIRENZ W/LAMIVUDINE/TENOFOVIR DISOPROXIL F,Congenital umbilical hernia;Foetal exposure during pregnancy,137953191,CA,,,137953191,3,20170705,20170705,,,137953191,1,Product used for unknown indication
13797035,137970351,1,I,20170706,20170720,20170727,20170727,EXP,,BR-HETERO LABS LTD-2023830,HETERO,,1,DY,,F,Y,3.73,KG,20170727,,OT,BR,BR,Efavirenz,Congenital pyelocaliectasis;Foetal exposure during pregnancy;Macrosomia,137970351,OT,,,137970351,1,20170417,,,,137970351,1,HIV infection
13801962,138019621,1,I,,20170717,20170727,20170727,EXP,,MX-GILEAD-2017-0285365,GILEAD,,46,YR,A,M,Y,,,20170727,,MD,MX,MX,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Delirium,138019621,OT,,,,,,,,,138019621,1,Product used for unknown indication
13816035,138160352,2,F,20170714,20170728,20170731,20170807,EXP,,MW-GILEAD-2017-0285542,GILEAD,,60,YR,A,M,Y,,,20170807,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,138160352,OT,,,138160352,1,20160525,20170713,,,138160352,1,Acquired immunodeficiency syndrome
13819073,138190733,3,F,20170721,20170802,20170801,20170807,EXP,,ZA-JNJFOC-20170718616,JANSSEN,,41,YR,A,F,Y,,,20170807,,MD,ZA,ZA,EFAVIRENZ,Asthenia,138190733,HO,,,138190733,1,20170330,20170403,,,138190733,1,Tuberculosis
13821004,138210041,1,I,,20170719,20170801,20170801,EXP,,DE-MYLANLABS-2017M1046613,MYLAN,"ARELIN V, SCHMIDT JJ, KAYSER N, KOHN-VELTEN WN, SUHLING H, EDEN G, ET AL. REMOVAL OF METHADONE BY EXTENDED DIALYSIS USING A HIGH CUT-OFF DIALYZER: IMPLICATIONS FOR THE TREATMENT OF OVERDOSE AND FOR PAIN MANAGEMENT IN PATIENTS UNDERGOING LIGHT CHAIN REMOVAL. NIEREN-HOCHDRUCKKR 2017;46(6):235-240.",,,,,Y,,,20170731,,OT,DE,DE,EFAVIRENZ,Acute kidney injury;Metabolic acidosis;Overdose;Toxicity to various agents,138210041,HO,,,,,,,,,138210041,1,Product used for unknown indication
13825128,138251281,1,I,201005,20170719,20170802,20170802,EXP,,MW-MYLANLABS-2017M1046886,MYLAN,"BARNETT BS, CHAWEZA T, TWEYA H, NGAMBI W, PHIRI S, HOSSEINIPOUR MC. ASSESSMENT OF NON-STANDARD HIV ANTIRETROVIRAL THERAPY REGIMENS AT LIGHTHOUSE TRUST IN LILONGWE, MALAWI. MALAWI-MED-J 2016;28(1):6-9.",,,,,Y,,,20170802,,OT,MW,MW,EFAVIRENZ,Abdominal discomfort;Confusional state;Depression;Hepatitis;Insomnia;Neuropathy peripheral,138251281,OT,,,138251281,1,201001,,,,138251281,1,HIV infection
13829320,138293201,1,I,201707,20170726,20170803,20170803,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-067153,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20170803,,PH,US,US,SUSTIVA,Cerebrovascular accident,138293201,LT,,,,,,,,,138293201,1,HIV infection
13832176,138321761,1,I,,20170721,20170803,20170803,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-069364,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,3.89,KG,20170803,,MD,US,US,EFAVIRENZ,Foetal exposure during pregnancy;HIV infection,138321761,OT,,,,,,,,,138321761,1,Product used for unknown indication
13832940,138329401,1,I,20140803,,20170803,20170803,DIR,FDA-CDER-CTU-2017-49207,,FDA-CTU,,48,YR,,M,N,,,20170803,N,OT,US,US,SUSTIVA,Neuropathy peripheral,,,138329401,HP,,,,,,,,,
13834780,138347801,1,I,20170727,20170727,20170804,20170804,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-068553,BRISTOL MYERS SQUIBB,,58,YR,,M,Y,,,20170804,,PH,US,US,SUSTIVA,Crohn's disease;Macular degeneration;Product storage error,138347801,OT,,,,,,,,,138347801,1,HIV infection
13842142,138421421,1,I,20170725,,20170807,20170807,DIR,FDA-CDER-CTU-2017-49997,,FDA-CTU,,66,YR,,M,N,,,20170807,N,PH,US,US,SUSTIVA,Dialysis;Renal disorder,,,138421421,HP,,,,,,,,,
13847395,138473951,1,I,20131022,20170731,20170808,20170808,EXP,,PT-009507513-1708PRT001228,MERCK,,36,YR,,F,Y,,,20170808,,MD,PT,PT,EFAVIRENZ,Anaemia of pregnancy;Caesarean section;Maternal exposure during pregnancy,138473951,OT,,,138473951,1,20131022,20131022,,,138473951,1,HIV infection
13849167,138491671,1,I,201005,20170727,20170809,20170809,EXP,,MW-CIPLA LTD.-2017MW13641,CIPLA,"BARNETT BS, CHAWEZA T, TWEYA H, NGAMBI W, PHIRI S, HOSSEINIPOUR MC. ASSESSMENT OF NON-STANDARD HIV ANTIRETROVIRAL THERAPY REGIMENS AT LIGHTHOUSE TRUST IN LILONGWE, MALAWI. MALAWI-MED-J. 2016;28 (1):6 TO 9",,,,,Y,,,20170809,,OT,MW,MW,Efavirenz,Abdominal discomfort;Confusional state;Depression;Hepatitis;Insomnia;Neuropathy peripheral,138491671,OT,,,138491671,2,201001,201009,,,138491671,1,HIV infection
13850768,138507681,1,I,,20170725,20170809,20170809,EXP,,GR-VIIV HEALTHCARE LIMITED-GR2017GSK123085,VIIV,"KOTSAFTI O, PAPARIZOS V, KOURKOUNTI S, CHATZIIOANNOU A, NICOLAIDOU E, KAPSIMALI V, ANTONIOU C. EARLY SYPHILIS AFFECTS MARKERS OF HIV. INTERNATIONAL JOURNAL OF STD + AIDS. 2016;27(9):739-745",,,,M,Y,,,20170809,,OT,GR,GR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,138507681,OT,,,,,,,,,138507681,1,HIV infection
13850786,138507861,1,I,,20170725,20170809,20170809,EXP,,GR-GLAXOSMITHKLINE-GR2017GSK123085,GLAXOSMITHKLINE,"KOTSAFTI O, PAPARIZOS V, KOURKOUNTI S, CHATZIIOANNOU A, NICOLAIDOU E, KAPSIMALI V, ANTONIOU C. EARLY SYPHILIS AFFECTS MARKERS OF HIV. INTERNATIONAL JOURNAL OF STD + AIDS. 2016;27(9):739-745",,,,M,Y,,,20170809,,OT,GR,GR,EFAVIRENZ,Pathogen resistance;Viral mutation identified,138507861,OT,,,,,,,,,138507861,1,HIV infection
13851067,138510672,2,F,,20170925,20170810,20170927,EXP,,CA-009507513-1708CAN004210,MERCK,,54,YR,,M,Y,,,20170927,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,138510672,OT,,,,,,,,,138510672,1,Product used for unknown indication
13851390,138513901,1,I,,20170801,20170809,20170809,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-069840,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20170809,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,138513901,OT,,,,,,,,,138513901,1,Product used for unknown indication
13857533,138575332,2,F,,20170803,20170811,20170811,EXP,,PHHY2017AU117179,NOVARTIS,"KOELSCH KK, RASMUSSEN TA, HEY-NGUYEN WJ, PEARSON C, XU Y, BAILEY M, ET AL.. IMPACT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ON THE HIV RESERVOIR AND IMMUNE RESPONSE IN 3 HIV-INFECTED INDIVIDUALS. J-ACQUIR-IMMUNE-DEFIC-SYNDR. 2017;75(3):328-37",,,,M,Y,,,20170811,,OT,AU,AU,EFAVIRENZ,Systemic candida,138575332,OT,,,138575332,1,201210,,,,138575332,1,Acute myeloid leukaemia
13867939,138679391,1,I,2017,20170807,20170814,20170814,EXP,,MX-GILEAD-2017-0287831,GILEAD,,46,YR,A,F,Y,,,20170814,,MD,MX,MX,EFAVIRENZ,Anxiety;Depression;Suicide attempt,138679391,OT,,,138679391,1,201704,,,,138679391,1,Product used for unknown indication
13869531,138695312,2,F,2016,20170831,20170815,20170905,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK124729,GLAXOSMITHKLINE,,34,YR,,M,Y,80,KG,20170905,,CN,CN,CN,EFAVIRENZ TABLET,Blood cholesterol abnormal;Blood creatinine increased;Blood triglycerides abnormal;Concomitant disease aggravated;Insomnia;Liver injury,138695312,OT,,,138695312,1,201508,201706,,,138695312,1,HIV infection
13869707,138697072,2,F,2016,20170831,20170815,20170905,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK124729,VIIV,,34,YR,,M,Y,80,KG,20170905,,CN,CN,CN,EFAVIRENZ TABLET,Blood cholesterol abnormal;Blood creatinine increased;Blood triglycerides abnormal;Concomitant disease aggravated;Insomnia;Liver injury,138697072,OT,,,138697072,1,201508,201706,,,138697072,1,HIV infection
13869743,138697431,1,I,201707,20170807,20170815,20170815,EXP,,US-GILEAD-2017-0287833,GILEAD,,58,YR,A,M,Y,,,20170815,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,138697431,OT,,,,,,,,,138697431,1,Product used for unknown indication
13873128,138731281,1,I,,20170803,20170816,20170816,EXP,,TH-CIPLA LTD.-2017TH14090,CIPLA,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J, ET AL;. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89 TO 96",,,,,Y,,,20170816,,OT,TH,TH,TENOFOVIR/LAMIVUDINE/EFAVIRENZ,Cervical dysplasia,138731281,OT,,,,,,,,,138731281,1,HIV infection
13873206,138732061,1,I,,20170803,20170816,20170816,EXP,,TH-CIPLA LTD.-2017TH14087,CIPLA,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL;. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89 TO 96",,,,,Y,,,20170816,,OT,TH,TH,TENOFOVIR/LAMIVUDINE/EFAVIRENZ,Virologic failure,138732061,OT,,,,,,,,,138732061,1,HIV infection
13873258,138732581,1,I,,20170806,20170816,20170816,EXP,,US-GILEAD-2017-0287765,GILEAD,,,,,M,Y,,,20170816,,MD,US,US,SUSTIVA,Renal failure,138732581,OT,,,,,,,,,138732581,1,Product used for unknown indication
13873279,138732791,1,I,,20170803,20170816,20170816,EXP,,TH-CIPLA LTD.-2017TH14091,CIPLA,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J, ET AL;. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89 TO 96",,,,,Y,,,20170816,,OT,TH,TH,TENOFOVIR/LAMIVUDINE/EFAVIRENZ,Endocarditis enterococcal,138732791,HO,,,,,,,,,138732791,1,HIV infection
13874864,138748641,1,I,,20170808,20170816,20170816,EXP,,CN-GILEAD-2017-0288119,GILEAD,,34,YR,A,M,Y,80,KG,20170816,,CN,CN,CN,EFAVIRENZ,Liver injury,138748641,OT,,,138748641,1,2014,201508,,,138748641,1,HIV infection
13878060,138780602,2,F,,20170821,20170817,20170830,EXP,,BW-GILEAD-2017-0288037,GILEAD,"ZASH R, JACOBSON D, DISEKO, MAYONDI G, MKHEMA J, MMALANE M, GAOLETHE T, PETLO C, HOLMES L, ESSEX M, LOCKMAN S, SHAPRIO R. DTG/TDF/FTC STARTED IN PREGNANCY IS AS SAFE AS EFV/TDF/FTC IN NATIONWIDE BIRTH OUTCOMES SURVEILLANCE IN BOTSWANA. IAS CONFERENCE SLIDE PRESENTATION. 2017;UNK:22",,,,,Y,,,20170830,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Skeletal dysplasia,138780602,OT,,,,,,,,,138780602,1,HIV infection
13878241,138782411,1,I,,20131105,20170817,20170817,PER,,US-ROCHE-1301472,ROCHE,"NADIR A, AMIN A, CHALISA  N AND VAN THIEL D. RETINAL VEIN THROMBOSIS ASSOCIATED WITH CHRONIC HEPATITIS C: A CASE SERIES AND REVIEW OF THE LITERATURE.. JOURNAL OF VIRAL HEPATITIS 2000 JAN 01;7:466-470.",58,YR,,M,Y,,,20170817,,OT,US,US,EFAVIRENZ,Nausea;Retinal vein thrombosis;Vomiting,,,,,138782411,2,1998,,,,138782411,1,Chronic hepatitis C
13881052,138810521,1,I,20170430,20170809,20170818,20170818,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-072999,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,78.5,KG,20170818,,OT,CN,CN,EFAVIRENZ,Hepatocellular injury,138810521,OT,,,138810521,1,20150411,20170609,,,138810521,1,HIV infection
13884510,138845101,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14200,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138845101,OT,,,,,,,,,138845101,1,HIV infection
13884653,138846531,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14198,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138846531,OT,,,,,,,,,138846531,1,HIV infection
13884681,138846811,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14197,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138846811,OT,,,,,,,,,138846811,1,HIV infection
13884708,138847081,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14211,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Stillbirth,138847081,OT,,,,,,,,,138847081,1,HIV infection
13884728,138847281,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14202,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138847281,OT,,,,,,,,,138847281,1,HIV infection
13884762,138847621,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14199,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138847621,OT,,,,,,,,,138847621,1,HIV infection
13884771,138847711,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14196,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138847711,OT,,,,,,,,,138847711,1,HIV infection
13884810,138848101,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14103,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Premature baby,138848101,OT,,,,,,,,,,,
13884816,138848161,1,I,,20170808,20170821,20170821,EXP,,ZA-TEVA-797740ISR,TEVA,,,,,M,Y,54,KG,20170821,,OT,ZA,ZA,EFV /FTC/TDF (EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE),Blood thyroid stimulating hormone increased;CD4 lymphocytes abnormal;CSF glucose increased;CSF protein increased;Haemoglobin decreased;Meningitis;Seizure,138848161,DE,,,138848161,1,20170412,,,,138848161,1,Tuberculosis
13884834,138848341,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14102,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138848341,OT,,,,,,,,,138848341,1,HIV infection
13884875,138848751,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14212,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Stillbirth,138848751,OT,,,,,,,,,138848751,1,HIV infection
13884879,138848791,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14201,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Premature delivery,138848791,OT,,,,,,,,,138848791,1,HIV infection
13884968,138849681,1,I,20170714,20170809,20170821,20170821,EXP,BX20171610,FR-VALIDUS PHARMACEUTICALS LLC-FR-2017VAL001235,VALIDUS,,59,YR,,M,Y,,,20170821,,OT,FR,FR,SUSTIVA,Hepatitis,138849681,HO,,,138849681,1,,20170715,,,138849681,1,Product used for unknown indication
13885001,138850011,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14213,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Stillbirth,138850011,OT,,,,,,,,,138850011,1,HIV infection
13885020,138850201,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14214,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Exposure during pregnancy;Stillbirth,138850201,OT,,,,,,,,,138850201,1,HIV infection
13885365,138853651,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14316,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Premature baby,138853651,OT,,,,,,,,,,,
13885801,138858011,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14319,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Premature baby,138858011,OT,,,,,,,,,,,
13885802,138858021,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14322,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Premature baby,138858021,OT,,,,,,,,,,,
13885804,138858041,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14321,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Premature baby,138858041,OT,,,,,,,,,,,
13885808,138858081,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14325,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Small for dates baby,138858081,OT,,,,,,,,,,,
13885812,138858121,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14320,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Premature baby,138858121,OT,,,,,,,,,,,
13885865,138858651,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14323,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Small for dates baby,138858651,OT,,,,,,,,,,,
13885873,138858731,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14326,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Small for dates baby,138858731,OT,,,,,,,,,,,
13885876,138858761,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14324,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Small for dates baby,138858761,OT,,,,,,,,,,,
13885879,138858791,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14317,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Premature baby,138858791,OT,,,,,,,,,,,
13885884,138858841,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14327,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Small for dates baby,138858841,OT,,,,,,,,,,,
13885889,138858891,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14318,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Premature baby,138858891,OT,,,,,,,,,,,
13885952,138859521,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14330,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Small for dates baby,138859521,OT,,,,,,,,,,,
13885954,138859541,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14329,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Small for dates baby,138859541,OT,,,,,,,,,,,
13886335,138863351,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14328,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Foetal exposure during pregnancy;Small for dates baby,138863351,OT,,,,,,,,,,,
13886337,138863371,1,I,,20170809,20170821,20170821,EXP,,US-CIPLA LTD.-2017BW14331,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170821,,OT,US,BW,Efavirenz,Death neonatal;Foetal exposure during pregnancy,138863371,DE,,,,,,,,,,,
13889055,138890551,1,I,,20170810,20170821,20170821,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-072982,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170821,,OT,US,US,SUSTIVA,Abnormal dreams,,,,,138890551,1,2011,,,,138890551,1,Product used for unknown indication
13889507,138895071,1,I,,20170809,20170822,20170822,EXP,,US-CIPLA LTD.-2017BW14332,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170822,,OT,US,BW,Efavirenz,Death neonatal;Foetal exposure during pregnancy,138895071,DE,,,,,,,,,,,
13889517,138895171,1,I,,20170809,20170822,20170822,EXP,,US-CIPLA LTD.-2017BW14333,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170822,,OT,US,BW,Efavirenz,Death neonatal;Foetal exposure during pregnancy,138895171,DE,,,,,,,,,,,
13889565,138895651,1,I,,20170809,20170822,20170822,EXP,,US-CIPLA LTD.-2017BW14334,CIPLA,"ZASH R, JACOBSON DL, DISEKO M, MAYONDI G, MMALANE M, ESSEX M ET AL;. COMPARATIVE SAFETY OF ANTIRETROVIRAL TREATMENT REGIMENS IN PREGNANCY. JAMA PEDIATRICS. 2017;E1 TO E9",,,,,Y,,,20170822,,OT,US,BW,Efavirenz,Death neonatal;Foetal exposure during pregnancy,138895651,DE,,,,,,,,,,,
13893877,138938771,1,I,,20170815,20170822,20170822,EXP,,US-GILEAD-2017-0289244,GILEAD,,,,A,M,Y,,,20170822,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Apparent death;Pyrexia;Urticaria,138938771,OT,,,,,,,,,138938771,1,Product used for unknown indication
13897383,138973831,1,I,,20170817,20170823,20170823,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017129197,VIIV,"VALVIESSE VRGA, DE PINHO LI, FREITAS RF, VARON AG, LEMOS AS. LAMIVUDINE^S HYPERSENSITIVITY IN AN HIV INFECTED PATIENT: CASE REPORT. MEDICINA (BRAZIL). 2017;50(2):139-142",50,YR,,F,Y,,,20170823,,OT,BR,BR,EFAVIRENZ,Erythema multiforme;Hypersensitivity;Stevens-Johnson syndrome,138973831,HO,,,,,,,,,138973831,1,Antiretroviral therapy
13897385,138973851,1,I,,20170817,20170823,20170823,EXP,,BR-GLAXOSMITHKLINE-BR2017129197,GLAXOSMITHKLINE,"VALVIESSE VRGA, DE PINHO LI, FREITAS RF, VARON AG, LEMOS AS. LAMIVUDINE^S HYPERSENSITIVITY IN AN HIV INFECTED PATIENT: CASE REPORT. MEDICINA (BRAZIL). 2017;50(2):139-142",50,YR,,F,Y,,,20170823,,OT,BR,BR,EFAVIRENZ,Erythema multiforme;Hypersensitivity;Stevens-Johnson syndrome,138973851,OT,,,,,,,,,138973851,1,Antiretroviral therapy
13900025,139000251,1,I,,20161130,20170823,20170823,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-104574,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20170823,,OT,ZA,ZA,EFAVIRENZ,Cerebellar ataxia,139000251,HO,,,,,,,,,139000251,1,HIV infection
13905611,139056111,1,I,,20170815,20170825,20170825,EXP,,ZA-TEVA-798382ISR,TEVA,,,,,M,Y,55,KG,20170825,,OT,ZA,ZA,EFAVIRENZ,Dyspnoea;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Malaise;Nasal flaring;Nosocomial infection;Pulmonary embolism;Pyrexia;Sepsis;Sinus tachycardia,139056111,HO,,,139056111,1,20170520,,,,139056111,1,Tuberculosis
13905647,139056471,1,I,20170719,20170815,20170825,20170825,EXP,,ZA-TEVA-799416ISR,TEVA,,29,YR,,M,Y,55,KG,20170825,,OT,ZA,ZA,EFAVIRENZ,Breath sounds abnormal;Chills;Dyspnoea;Lymphadenopathy;Neck pain;Pleuritic pain;Pyrexia;Respiratory rate increased;Sinus tachycardia,139056471,HO,,,139056471,1,20170520,,,,139056471,1,Tuberculosis
13905753,139057531,1,I,,20170818,20170825,20170825,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130750,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139057531,OT,,,139057531,1,20151010,,,,139057531,1,HIV infection
13906408,139064083,3,F,200706,20170911,20170825,20170914,EXP,,CA-009507513-0809CAN00001,MERCK,,54,YR,,M,Y,,,20170914,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,139064083,OT,,,139064083,1,2004,,,,139064083,1,Product used for unknown indication
13906966,139069661,1,I,,20170818,20170825,20170825,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130749,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139069661,OT,,,139069661,1,20151008,,,,139069661,1,HIV infection
13906967,139069671,1,I,,20170818,20170825,20170825,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130750,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139069671,OT,,,139069671,1,20151010,,,,139069671,1,HIV infection
13906968,139069681,1,I,,20170818,20170825,20170825,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130749,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139069681,OT,,,139069681,1,20151008,,,,139069681,1,HIV infection
13907006,139070061,1,I,,20170818,20170825,20170825,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130752,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139070061,OT,,,139070061,1,20150909,,,,139070061,1,HIV infection
13907007,139070071,1,I,,20170818,20170825,20170825,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130752,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170825,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139070071,OT,,,139070071,1,20150909,,,,139070071,1,HIV infection
13908647,139086471,1,I,,20170818,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130755,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086471,OT,,,139086471,1,20150930,,,,139086471,1,HIV infection
13908648,139086481,1,I,,20170818,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130753,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086481,OT,,,139086481,1,20151109,,,,139086481,1,HIV infection
13908649,139086491,1,I,,20170818,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130758,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086491,OT,,,139086491,1,20150701,,,,139086491,1,HIV infection
13908650,139086501,1,I,,20170818,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130757,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086501,OT,,,139086501,1,20150819,,,,139086501,1,HIV infection
13908651,139086511,1,I,,20170818,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130756,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086511,OT,,,139086511,1,20141028,,,,139086511,1,HIV infection
13908652,139086521,1,I,,20170818,20170827,20170827,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK130754,GLAXOSMITHKLINE,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086521,OT,,,139086521,1,20150209,,,,139086521,1,HIV infection
13908653,139086531,1,I,,20170818,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130755,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086531,OT,,,139086531,1,20150930,,,,139086531,1,HIV infection
13908654,139086541,1,I,,20170818,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130753,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086541,OT,,,139086541,1,20151109,,,,139086541,1,HIV infection
13908655,139086551,1,I,,20170818,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130758,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086551,OT,,,139086551,1,20150701,,,,139086551,1,HIV infection
13908656,139086561,1,I,,20170818,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130757,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086561,OT,,,139086561,1,20150819,,,,139086561,1,HIV infection
13908657,139086571,1,I,,20170818,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130756,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086571,OT,,,139086571,1,20141028,,,,139086571,1,HIV infection
13908658,139086581,1,I,,20170818,20170827,20170827,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK130754,VIIV,"LI T, QIAN F, YUAN T, XU W, ZHU L, HUANG J ET AL. DRUG RESISTANCE MUTATION PROFILES OF THE DRUG-NA?VE AND FIRST-LINE REGIMEN-TREATED HIV-1-INFECTED POPULATION OF SUZHOU, CHINA. VIROLOGICA SINICA. 2017;1-9",,,,,Y,,,20170827,,OT,CN,CN,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,139086581,OT,,,139086581,1,20150209,,,,139086581,1,HIV infection
13909830,139098301,1,I,,20170821,20170828,20170828,EXP,,ZA-HETERO-HET2017ZA00116,HETERO,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL.. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES.. J-ACQUIR-IMMUNE-DEFIC-SYNDR. 2017;75(5):577-579",,,,F,Y,,,20170828,,OT,ZA,ZA,Efavirenz,Ataxia,139098301,HO,,,,,,,,,139098301,1,HIV infection
13909831,139098312,2,F,,20170821,20170828,20170904,EXP,,ZA-HETERO CORPORATE-HET2017ZA00115,HETERO,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL.. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES.. J-ACQUIR-IMMUNE-DEFIC-SYNDR. 2017;75(5):577-579",,,,F,Y,,,20170904,,OT,ZA,ZA,Efavirenz,Ataxia,139098312,HO,,,,,,,,,139098312,1,HIV infection
13910385,139103851,1,I,,20170814,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052768,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139103851,HO,,,,,,,,,139103851,1,HIV infection
13910386,139103861,1,I,,20170814,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052745,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139103861,HO,,,,,,,,,139103861,1,HIV infection
13910411,139104111,1,I,,20170814,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052744,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139104111,HO,,,,,,,,,139104111,1,HIV infection
13910633,139106331,1,I,,20170814,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052825,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139106331,HO,,,,,,,,,139106331,1,HIV infection
13910636,139106361,1,I,,20170814,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052778,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139106361,HO,,,,,,,,,139106361,1,HIV infection
13910637,139106371,1,I,,20170814,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052842,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139106371,HO,,,,,,,,,139106371,1,HIV infection
13910838,139108381,1,I,,20170814,20170828,20170828,EXP,,ZA-MYLANLABS-2017M1052863,MYLAN,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET AL. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2017;75(5):577-579.",,,A,F,Y,,,20170828,,MD,ZA,ZA,EFAVIRENZ,Ataxia;Toxicity to various agents,139108381,HO,,,,,,,,,139108381,1,HIV infection
13911432,139114321,1,I,2014,20170823,20170828,20170828,PER,,US-GLAXOSMITHKLINE-US2017GSK131689,GLAXOSMITHKLINE,,54,YR,,M,Y,96.6,KG,20170828,,CN,US,US,SUSTIVA,Amnesia;Drug dose omission;Memory impairment,,,,,139114321,1,1999,20141118,,,139114321,1,HIV infection
13911778,139117781,1,I,2014,20170823,20170828,20170828,PER,,US-VIIV HEALTHCARE LIMITED-US2017GSK131689,VIIV,,54,YR,,M,Y,96.6,KG,20170828,,CN,US,US,SUSTIVA,Amnesia;Drug dose omission;Memory impairment,,,,,139117781,1,1999,20141118,,,139117781,1,HIV infection
13914640,139146404,4,F,20170813,20170915,20170829,20170920,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-076816,BRISTOL MYERS SQUIBB,,3,MON,,M,Y,3.65,KG,20170920,,OT,BR,BR,EFAVIRENZ,Bronchiolitis;Foetal exposure during pregnancy;Pneumonia bacterial,139146404,OT,,,139146404,1,20170309,20170319,,,139146404,1,Prophylaxis against HIV infection
13924142,139241421,1,I,,20170816,20170831,20170831,EXP,,BR-LUPIN PHARMACEUTICALS INC.-2017-05106,LUPIN,,50,YR,,F,Y,,,20170831,,OT,BR,BR,EFAVIRENZ,Hypersensitivity;Stevens-Johnson syndrome,139241421,HO,,,,,,,,,139241421,1,Acquired immunodeficiency syndrome
13924232,139242321,1,I,,20170822,20170831,20170831,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-078162,BRISTOL MYERS SQUIBB,,49,YR,,F,Y,,,20170831,,OT,MW,MW,EFAVIRENZ,Labelled drug-drug interaction medication error;Plasmodium malariae infection,139242321,OT,,,,,,,,,139242321,1,HIV infection
13924235,139242351,1,I,,20170822,20170831,20170831,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-078356,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20170831,,OT,MW,MW,EFAVIRENZ,Labelled drug-drug interaction medication error;Plasmodium malariae infection,139242351,OT,,,,,,,,,139242351,1,HIV infection
13925619,139256192,2,F,,20170907,20170831,20170913,EXP,,UG-SA-2017SA157037,AVENTIS,,40,YR,A,F,Y,,,20170913,,OT,GB,UG,EFAVIRENZ,Anticoagulation drug level above therapeutic;Drug interaction;Epistaxis,139256192,OT,,,,,,,,,139256192,2,HIV infection
13925622,139256222,2,F,,20170907,20170831,20170915,EXP,,UG-SA-2017SA157039,AVENTIS,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J, ET AL. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY 2016;16(1):16. DOI: 10.1186/S12878-016-0056-6. ACCESSED ON: 2016 JUN 04.",27,YR,A,M,Y,,,20170915,,OT,UG,UG,EFAVIRENZ,Anticoagulation drug level above therapeutic;Drug interaction;Epistaxis,139256222,OT,,,,,,,,,139256222,2,Cryptococcus test positive
13927942,139279421,1,I,,20170822,20170901,20170901,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2017GSK134316,VIIV,"DADABHAI S, GADAMA L, CHAMANGA R, KAWALAZIRA R, KATUMBI C, DULA D. PREGNANCY OUTCOMES AND INFANT SURVIVAL IN THE ERA OF UNIVERSAL HAART IN AFRICA: THE POISE STUDY. 9TH CONFERENCE ON HIV SCIENCE - INTERNATIONAL AIDS SOCIETY. 2017",,,I,,Y,,,20170901,,OT,MW,MW,EFAVIRENZ,Death;Foetal exposure during pregnancy,139279421,DE,,,,,,,,,,,
13927943,139279431,1,I,,20170822,20170901,20170901,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2017GSK134319,VIIV,"DADABHAI S, GADAMA L, CHAMANGA R, KAWALAZIRA R, KATUMBI C, DULA D. PREGNANCY OUTCOMES AND INFANT SURVIVAL IN THE ERA OF UNIVERSAL HAART IN AFRICA: THE POISE STUDY. 9TH CONFERENCE ON HIV SCIENCE - INTERNATIONAL AIDS SOCIETY. 2017",,,I,,Y,,,20170901,,OT,MW,MW,EFAVIRENZ,Death;Foetal exposure during pregnancy,139279431,DE,,,,,,,,,,,
13927961,139279611,1,I,,20170822,20170901,20170901,EXP,,MW-GLAXOSMITHKLINE-MW2017GSK134316,GLAXOSMITHKLINE,"DADABHAI S, GADAMA L, CHAMANGA R, KAWALAZIRA R, KATUMBI C, DULA D. PREGNANCY OUTCOMES AND INFANT SURVIVAL IN THE ERA OF UNIVERSAL HAART IN AFRICA: THE POISE STUDY. 9TH CONFERENCE ON HIV SCIENCE - INTERNATIONAL AIDS SOCIETY. 2017",,,I,,Y,,,20170901,,OT,MW,MW,EFAVIRENZ,Death;Foetal exposure during pregnancy,139279611,OT,,,,,,,,,,,
13927964,139279641,1,I,,20170822,20170901,20170901,EXP,,MW-GLAXOSMITHKLINE-MW2017GSK134319,GLAXOSMITHKLINE,"DADABHAI S, GADAMA L, CHAMANGA R, KAWALAZIRA R, KATUMBI C, DULA D. PREGNANCY OUTCOMES AND INFANT SURVIVAL IN THE ERA OF UNIVERSAL HAART IN AFRICA: THE POISE STUDY. 9TH CONFERENCE ON HIV SCIENCE - INTERNATIONAL AIDS SOCIETY. 2017",,,I,,Y,,,20170901,,OT,MW,MW,EFAVIRENZ,Death;Foetal exposure during pregnancy,139279641,OT,,,,,,,,,,,
13928785,139287852,2,F,,20170825,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14993,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A ET AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75(5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Cerebellar syndrome;Delirium;Diarrhoea;Drug level increased;Speech disorder;Vomiting,139287852,OT,,,,,,,,,139287852,1,HIV infection
13928788,139287882,2,F,,20170825,20170901,20170908,EXP,,ZA-CIPLA LTD.-2017ZA14994,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170908,,OT,ZA,ZA,Efavirenz;TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Cerebellar syndrome;Cholestasis;Drug level increased;Speech disorder,139287882,HO,,,,,,,,,139287882,1,HIV infection
13928802,139288022,2,F,,20170825,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14995,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,Efavirenz;TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Aggression;Asthenia;Ataxia;Burning sensation;Cerebellar syndrome;Delirium;Drug level increased;Dysarthria,139288022,HO,,,,,,,,,139288022,1,HIV infection
13928968,139289682,2,F,,20170825,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14996,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,Efavirenz,Ataxia;Cerebellar syndrome;Drug level increased;Dysarthria;Hepatic enzyme increased,139289682,HO,,,,,,,,,139289682,1,HIV infection
13928971,139289712,2,F,,20170825,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14997,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75(5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Confusional state;Death;Drug level increased;Treatment noncompliance;Viral load increased,139289712,DE,,,,,,,,,139289712,1,HIV infection
13929001,139290012,2,F,,20170825,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA15001,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A ET AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Death;Drug level increased;Encephalopathy,139290012,DE,,,,,,,,,139290012,1,HIV infection
13929008,139290082,2,F,,20170825,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14998,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A ET AL;. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Drug level increased;Seizure,139290082,HO,,,,,,,,,139290082,1,HIV infection
13930783,139307831,1,I,,20170828,20170901,20170901,EXP,,KE-GILEAD-2017-0291241,GILEAD,"SOME F, KOECH M, CHESIRE E, KIGEN G.. REVERSAL OF TENOFOVIR INDUCED NEPHROTOXICITY: CASE REPORTS OF TWO PATIENTS.. PAN AFRICAN MEDICAL JOURNAL. 2017;27:UNK",54,YR,A,M,Y,,,20170901,,OT,KE,KE,EFAVIRENZ,Acute kidney injury;Nephropathy toxic,139307831,HO,,,,,,,,,139307831,1,HIV infection
13931860,139318601,1,I,,20170822,20170904,20170904,EXP,,MY-APPCO PHARMA LLC-2025511,APPCO PHARMA,,43,YR,,F,Y,,,20170904,,OT,MY,MY,efavirenz,Rash maculo-papular;Rash pruritic,139318601,HO,,,,,,,,,139318601,1,Antiretroviral therapy
13933593,139335931,1,I,2014,20170823,20170904,20170904,PER,,US-TAKEDA-2017TUS017875,TAKEDA,,54,YR,,M,Y,96.6,KG,20170904,,CN,US,US,SUSTIVA,Amnesia;Drug dose omission;Memory impairment,,,,,139335931,1,20141105,20170501,,,139335931,1,Dyspepsia
13934229,139342291,1,I,,20170823,20170905,20170905,EXP,,US-GLENMARK PHARMACEUTICALS-2017GMK028672,GLENMARK,"ALI M S, CIFTCI F D, KOORAGAYALU S, MBA B, KOHLI A, GHORI U ET AL.. AN UNUSUAL COMPLICATION OF INHALED CORTICOSTEROIDS IN AN HIV INFECTED PATIENT.. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.. 2017;195",58,YR,,M,Y,,,20170904,,MD,US,US,EFAVIRENZ,Drug interaction;Fall;Myopathy;Toxicity to various agents,139342291,HO,,,,,,,,,139342291,1,Chronic obstructive pulmonary disease
13936025,139360251,1,I,,20170822,20170905,20170905,EXP,,US-VIIV HEALTHCARE LIMITED-MW2017GSK134860,VIIV,,,,,F,Y,,,20170905,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139360251,OT,,,,,,,,,139360251,1,HIV infection
13936026,139360261,1,I,,20170822,20170905,20170905,EXP,,US-VIIV HEALTHCARE LIMITED-MW2017GSK134859,VIIV,,,,,F,Y,,,20170905,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139360261,OT,,,,,,,,,139360261,1,HIV infection
13936027,139360271,1,I,,20170822,20170905,20170905,EXP,,US-VIIV HEALTHCARE LIMITED-MW2017GSK134825,VIIV,,,,,F,Y,,,20170905,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139360271,OT,,,,,,,,,139360271,1,HIV infection
13936219,139362191,1,I,,20170822,20170905,20170905,EXP,,MW-MYLANLABS-2017M1054569,MYLAN,"NYANGULU WJ, MWINJIWA E, DIVALA TH, MUNGWIRA RG, NYIRENDA O, KANJALA M, ET AL. FREQUENT MALARIA ILLNESS EPISODES IN TWO MALAWIAN PATIENTS ON ANTIRETROVIRAL THERAPY SOON AFTER STOPPING COTRIMOXAZOLE PREVENTIVE THERAPY. MALAWI-MED-J 2017;29(1):57-60.",49,YR,,F,Y,,,20170904,,OT,MW,MW,EFAVIRENZ,Drug interaction;Treatment failure,139362191,OT,,,,,,,,,139362191,1,Plasmodium malariae infection
13936247,139362471,1,I,,20170822,20170905,20170905,EXP,,US-GLAXOSMITHKLINE-MW2017GSK134860,GLAXOSMITHKLINE,,,,,F,Y,,,20170905,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139362471,OT,,,,,,,,,139362471,1,HIV infection
13936253,139362531,1,I,,20170822,20170905,20170905,EXP,,US-GLAXOSMITHKLINE-MW2017GSK134859,GLAXOSMITHKLINE,,,,,F,Y,,,20170905,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139362531,OT,,,,,,,,,139362531,1,HIV infection
13936254,139362541,1,I,,20170822,20170905,20170905,EXP,,US-GLAXOSMITHKLINE-MW2017GSK134825,GLAXOSMITHKLINE,,,,,F,Y,,,20170905,,OT,MW,MW,EFAVIRENZ,Alanine aminotransferase increased;Exposure during pregnancy;Hepatotoxicity;Live birth,139362541,OT,,,,,,,,,139362541,1,HIV infection
13938334,139383342,2,F,,20170906,20170905,20170914,EXP,,US-GILEAD-2017-0291942,GILEAD,,46,YR,A,F,Y,,,20170914,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Intentional product use issue,139383342,OT,,,139383342,1,1997,,,,139383342,1,HIV infection
13938958,139389582,2,F,,20170906,20170906,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16065,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Cerebellar syndrome;Drug level increased,139389582,OT,,,,,,,,,139389582,1,Antiretroviral therapy
13940444,139404442,2,F,,20170830,20170906,20170914,EXP,,BR-MYLANLABS-2017M1054536,MYLAN,"VALVIESSE VRGA, DE PINHO LI, FREITAS RF, VARON AG, LEMOS AS. LAMIVUDINE^S HYPERSENSITIVITY IN AN HIV INFECTED PATIENT: CASE REPORT. MEDICINA-BRAZIL 2017;50(2):139-142.",50,YR,,F,Y,,,20170914,,OT,BR,BR,EFAVIRENZ,Hypersensitivity;Stevens-Johnson syndrome,139404442,OT,,,,,,,,,139404442,1,HIV infection
13940910,139409101,1,I,,20170822,20170906,20170906,EXP,,MW-MYLANLABS-2017M1054625,MYLAN,"NYANGULU WJ, MWINJIWA E, DIVALA TH, MUNGWIRA RG, NYIRENDA O, KANJALA M, ET AL. FREQUENT MALARIA ILLNESS EPISODES IN TWO MALAWIAN PATIENTS ON ANTIRETROVIRAL THERAPY SOON AFTER STOPPING COTRIMOXAZOLE PREVENTIVE THERAPY. MALAWI-MED-J 2017;29(1):57-60.",37,YR,,F,Y,,,20170906,,OT,MW,MW,EFAVIRENZ,Drug interaction;Treatment failure,139409101,OT,,,,,,,,,139409101,1,Plasmodium malariae infection
13942829,139428291,1,I,,20170901,20170906,20170906,PER,,US-GILEAD-2017-0292094,GILEAD,,,,A,F,Y,,,20170906,,CN,US,US,SUSTIVA,Arthralgia;Myalgia,,,,,,,,,,,139428291,1,Product used for unknown indication
13943526,139435261,1,I,,20170825,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16060,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Abnormal behaviour;Ataxia;Cerebellar syndrome;Drug level increased;Malaise;Paraesthesia;Suicidal ideation;Tremor;Vomiting,139435261,HO,,,,,,,,,139435261,1,HIV infection
13944690,139446901,1,I,,20170825,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16040,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Cerebellar syndrome;Exposure during pregnancy;Fall;Speech disorder,139446901,OT,,,,,,,,,139446901,1,HIV infection
13944693,139446931,1,I,,20170825,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16059,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Abnormal behaviour;Acute psychosis;Ataxia;Confusional state;Death;Drug level increased;Dyskinesia,139446931,HO,,,,,,,,,139446931,1,HIV infection
13944700,139447001,1,I,,20170825,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16058,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A ET AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Drug level increased;Encephalopathy;Immune reconstitution inflammatory syndrome,139447001,HO,,,,,,,,,139447001,1,HIV infection
13945823,139458231,1,I,,20170825,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16062,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Acute kidney injury;Ataxia;Drug level increased;Encephalopathy;International normalised ratio increased;Leukocytosis;Sepsis;Thrombocytopenia,139458231,HO,,,,,,,,,139458231,1,HIV infection
13948042,139480421,1,I,,20170906,20170908,20170908,PER,,US-PFIZER INC-2017391008,PFIZER,,58,YR,,M,Y,,,20170908,,OT,US,US,SUSTIVA,Drug hypersensitivity,,,,,,,,,,,,,
13951607,139516072,2,F,20161114,20170918,20170908,20170922,EXP,,ZA-GILEAD-2017-0292226,GILEAD,,31,YR,A,F,Y,,,20170922,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,139516072,OT,,,,,,,,,139516072,1,HIV infection
13955320,139553201,1,I,,20170905,20170911,20170911,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2017GSK140190,VIIV,,,,,M,Y,,,20170911,,MD,CO,CO,EFAVIRENZ,Drug ineffective;Treatment noncompliance,139553201,LT,,,,,,,,,139553201,1,HIV infection
13964540,139645401,1,I,,20170907,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140679,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645401,OT,,,,,,,,,139645401,1,HIV infection
13964541,139645411,1,I,,20170907,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140676,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645411,OT,,,,,,,,,139645411,1,HIV infection
13964543,139645431,1,I,,20170907,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140681,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645431,OT,,,,,,,,,139645431,1,HIV infection
13964544,139645441,1,I,,20170907,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140674,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016.",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645441,OT,,,,,,,,,139645441,1,HIV infection
13964547,139645471,1,I,,20170907,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140679,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645471,OT,,,,,,,,,139645471,1,HIV infection
13964548,139645481,1,I,,20170907,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140676,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645481,OT,,,,,,,,,139645481,1,HIV infection
13964550,139645501,1,I,,20170907,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140681,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645501,OT,,,,,,,,,139645501,1,HIV infection
13964551,139645511,1,I,,20170907,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140674,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016.",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139645511,OT,,,,,,,,,139645511,1,HIV infection
13965189,139651891,1,I,,20170910,20170913,20170913,EXP,,PE-BAYER-2017-174607,BAYER,MONTALVO R; TICONA E; NAVINCOPA M; GARCIA Y; CHAVEZ G; CHAVEZ V; AREVALO J; SORIA J; HUIZA A. RECURRENT DIARRHEA DUE TO CYSTOISOPORA BELLI IN HIV/AIDS PATIENTS RECEIVING HAART. REV PERU MED EXP SALUD PUBLICA. 2013;30 (2):326-330,34,YR,A,M,Y,,,20170913,,OT,PE,PE,EFAVIRENZ,Drug ineffective,139651891,HO,,,,,,,,,139651891,7,Prophylaxis
13965858,139658581,1,I,,20170907,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140684,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139658581,OT,,,,,,,,,139658581,1,HIV infection
13965860,139658601,1,I,,20170907,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140684,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139658601,OT,,,,,,,,,139658601,1,HIV infection
13966087,139660871,1,I,,20170907,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140689,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660871,OT,,,,,,,,,139660871,1,HIV infection
13966088,139660881,1,I,,20170907,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140693,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660881,OT,,,,,,,,,139660881,1,HIV infection
13966091,139660911,1,I,,20170907,20170913,20170913,EXP,,GB-GLAXOSMITHKLINE-ZA2017140691,GLAXOSMITHKLINE,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660911,OT,,,,,,,,,139660911,1,HIV infection
13966094,139660941,1,I,,20170907,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140693,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660941,OT,,,,,,,,,139660941,1,HIV infection
13966095,139660951,1,I,,20170907,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140689,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660951,OT,,,,,,,,,139660951,1,HIV infection
13966098,139660981,1,I,,20170907,20170913,20170913,EXP,,GB-VIIV HEALTHCARE LIMITED-ZA2017140691,VIIV,"COLLIER D, IWUJI C, DERACHE A, DE OLIVEIRA T, OKESOLA N, CALMY A.ET.AL. VIROLOGICAL OUTCOMES OF SECOND-LINE PROTEASE INHIBITOR-BASED TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN A HIGH-PREVALENCE RURAL SOUTH AFRICAN SETTING: A COMPETING-RISKS PROSPECTIVE COHORT ANALYSIS. CLINICAL INFECTIOUS DISEASES. 2017;64(8):1006-1016",,,,,Y,,,20170913,,MD,GB,ZA,EFAVIRENZ,Viral mutation identified;Virologic failure,139660981,OT,,,,,,,,,139660981,1,HIV infection
13977826,139778261,1,I,199804,20011121,20170915,20170915,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-11598133,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20170915,,MD,JP,JP,EFAVIRENZ,Acute kidney injury;Amylase increased;Death;Diarrhoea;Hyperlactacidaemia;Hyperlipidaemia;Lactic acidosis;Neuropathy peripheral;Pancreatitis acute,139778261,OT,,,139778261,1,19950801,20001208,,,139778261,1,Acquired immunodeficiency syndrome
13978139,139781391,1,I,,20170814,20170915,20170915,EXP,,UG-CIPLA LTD.-2017UG16293,CIPLA,,,,,,Y,,,20170915,,MD,UG,UG,TENOFOVIR/LAMIVUDINE/EFAVIRENZ,Burning sensation;Lip erythema;Product substitution issue,139781391,OT,,,,,,,,,,,
13978834,139788341,1,I,,20170117,20170915,20170915,EXP,,CA-009507513-1709CAN006796,MERCK,,54,YR,,M,Y,,,20170915,,CN,US,CA,SUSTIVA,Depression;Drug interaction,139788341,OT,,,,,,,,,139788341,1,Product used for unknown indication
13980436,139804361,1,I,,20170913,20170918,20170918,EXP,,UG-HETERO CORPORATE-HET2017UG00185,HETERO,,28,YR,,F,Y,,,20170918,,OT,UG,UG,Efavirenz,Exposure during pregnancy;Foetal death,139804361,OT,,,139804361,1,20170309,20170313,,,139804361,1,HIV infection
13980932,139809321,1,I,20170818,,20170915,20170915,DIR,FDA-CDER-CTU-2017-59778,,FDA-CTU,,66,YR,,M,N,,,20170822,N,PH,US,,EFAVIRENZ,Chest pain;Diarrhoea;Dyspnoea;Haemoglobin decreased;International normalised ratio increased;Oedema,139809321,HO,139809321,HP,139809321,1,20170818,,,,139809321,1,Anticoagulant therapy
13990215,139902151,1,I,,20170913,20170920,20170920,EXP,,FR-GLAXOSMITHKLINE-FR2017GSK145845,GLAXOSMITHKLINE,,67,YR,,F,Y,,,20170920,,MD,FR,FR,EFAVIRENZ,Drug ineffective;Renal failure;Virologic failure,139902151,OT,,,,,,,,,139902151,1,HIV infection
13990283,139902831,1,I,20170509,20170913,20170920,20170920,EXP,,UG-GLAXOSMITHKLINE-UG2017GSK145019,GLAXOSMITHKLINE,,28,YR,,F,Y,,,20170920,,CN,US,UG,EFAVIRENZ,Exposure during pregnancy;Hepatotoxicity;Stillbirth,139902831,OT,,,139902831,1,20170314,20170313,,,139902831,1,HIV infection
13990685,139906851,1,I,,20170913,20170920,20170920,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017GSK145845,VIIV,,67,YR,,F,Y,,,20170920,,MD,FR,FR,EFAVIRENZ,Drug ineffective;Renal failure;Virologic failure,139906851,OT,,,,,,,,,139906851,1,HIV infection
13990715,139907151,1,I,20170509,20170913,20170920,20170920,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2017GSK145019,VIIV,,28,YR,,F,Y,,,20170920,,CN,US,UG,EFAVIRENZ,Exposure during pregnancy;Hepatotoxicity;Stillbirth,139907151,OT,,,139907151,1,20170314,20170313,,,139907151,1,HIV infection
13993776,139937761,1,I,201612,20170911,20170920,20170920,EXP,,US-GILEAD-2017-0293547,GILEAD,,47,YR,A,M,Y,,,20170920,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Amyotrophic lateral sclerosis,139937761,OT,,,139937761,1,2015,,,,139937761,1,HIV infection
13998640,139986401,1,I,,20170919,20170922,20170922,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK147294,VIIV,WEIXUAN L. ANALYSIS OF ADVERSE REACTIONS OF DIFFERENT HAART REGIMENS IN 120 AIDS PATIENTS IN A HOSPITAL. PHARMACY TODAY. 2017;27(5):341-342,,,,,Y,,,20170922,,OT,CN,CN,EFAVIRENZ,Hepatic cirrhosis,139986401,OT,,,,,,,,,,,
13999007,139990071,1,I,,20170919,20170922,20170922,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK147294,GLAXOSMITHKLINE,WEIXUAN L. ANALYSIS OF ADVERSE REACTIONS OF DIFFERENT HAART REGIMENS IN 120 AIDS PATIENTS IN A HOSPITAL. PHARMACY TODAY. 2017;27(5):341-342,,,,,Y,,,20170922,,OT,CN,CN,EFAVIRENZ,Hepatic cirrhosis,139990071,OT,,,,,,,,,,,
14003044,140030441,1,I,,20170124,20170922,20170922,EXP,,BR-SUN PHARMACEUTICAL INDUSTRIES LTD-2017US-146096,RANBAXY,,38,WK,,F,Y,,,20170922,,CN,US,BR,Lamivudine/Efavirenz/Tenofovir,Congenital umbilical hernia;Foetal exposure during pregnancy;Umbilical hernia,140030441,OT,,,140030441,1,20161214,20170705,,,140030441,1,Supplementation therapy
14003049,140030492,2,F,,20170911,20170922,20170925,EXP,,BR-SUN PHARMACEUTICAL INDUSTRIES LTD-2017US-149993,RANBAXY,,38,WK,,F,Y,,,20170925,,CN,US,BR,Lamivudine/Efavirenz/Tenofovir,Foetal exposure during pregnancy;Umbilical hernia,140030492,OT,,,140030492,1,20161214,20170705,,,140030492,1,Supplementation therapy
14007249,140072491,1,I,20170923,,20170924,20170924,DIR,US-FDA-384439,,FDA-CTU,,29,YR,,M,N,77,KG,20170924,N,CN,BR,BR,EFAVIRENZ,Abdominal pain;Decreased appetite;Malaise;Nausea;Panic attack;Weight decreased,140072491,HO,140072491,CSM,140072491,1,20170918,,,,140072491,1,Irritable bowel syndrome
14012510,140125101,1,I,2014,20170823,20170926,20170926,PER,,US-ABBVIE-17P-163-2082230-00,ABBVIE,,54,YR,,M,Y,96.6,KG,20170926,,MD,US,US,SUSTIVA,Amnesia;Drug dose omission;Memory impairment,,,,,140125101,1,1999,20141118,,,140125101,1,HIV infection
14015494,140154941,1,I,20170827,20170918,20170927,20170927,EXP,PT-INFARMED-J201709-4,PT-TEVA-808793ISR,TEVA,,62,YR,,M,Y,60,KG,20170927,,PH,PT,PT,EFAVIRENZ TEVA,Abdominal distension;Abnormal dreams;Diarrhoea;Fatigue;Nightmare;Product substitution issue,140154941,OT,,,140154941,1,20170622,,,,140154941,1,HIV infection
14017096,140170961,1,I,20170309,20170913,20170927,20170927,EXP,,UG-MYLANLABS-2017M1058627,MYLAN,,,,,M,Y,3,KG,20170922,,OT,UG,UG,EFAVIRENZ,Foetal exposure during pregnancy;Stillbirth,140170961,DE,,,140170961,1,20170309,20170313,,,140170961,1,HIV infection
14017101,140171011,1,I,,20170913,20170927,20170927,EXP,,UG-MYLANLABS-2017M1058622,MYLAN,,,,,M,Y,,,20170921,,OT,UG,UG,EFAVIRENZ,Foetal exposure during pregnancy;Polydactyly;Syndactyly,140171011,OT,,,140171011,1,20170530,,,,140171011,1,HIV infection
14017614,140176141,1,I,,20170919,20170927,20170927,EXP,,GB-GILEAD-2017-0294770,GILEAD,,,,A,M,Y,,,20170927,,CN,GB,GB,EFAVIRENZ,Death,140176141,OT,,,,,,,,,140176141,1,Product used for unknown indication
14018138,140181381,1,I,,20170913,20170928,20170928,EXP,,UG-CIPLA LTD.-2017UG17389,CIPLA,,,,,,Y,,,20170927,,CN,UG,UG,Efavirenz,Exposure during pregnancy;Stillbirth,140181381,OT,,,140181381,1,20170309,20170313,,,140181381,1,HIV infection
14018140,140181401,1,I,20170509,20170913,20170928,20170928,EXP,,UG-CIPLA LTD.-2017UG17700,CIPLA,,,,,,Y,,,20170927,,CN,UG,UG,Efavirenz,Foetal exposure during pregnancy;Hepatotoxicity,140181401,DE,,,,,,,,,,,
14021516,140215161,1,I,,20170920,20170928,20170928,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-084601,BRISTOL MYERS SQUIBB,,59,YR,,M,Y,,,20170928,,PH,US,US,SUSTIVA,Adverse event,140215161,HO,,,,,,,,,140215161,1,Product used for unknown indication
14023490,140234901,1,I,20170912,20170919,20170929,20170929,PER,,US-BIOGEN-2017BV000320,BIOGEN,,58,YR,,M,Y,,,20170929,,CN,US,US,EFAVIRENZ,Musculoskeletal pain,,,,,140234901,1,20161215,,,,140234901,1,Factor VIII deficiency
14024343,140243431,1,I,20170801,20170928,20170929,20170929,EXP,GB-MHRA-EYC 00163243,GB-VIIV HEALTHCARE LIMITED-GB2017150413,VIIV,,26,YR,,F,Y,68,KG,20170929,,MD,GB,GB,EFAVIRENZ,Acute kidney injury;Feeling hot;Flushing;Hypersensitivity;Hypotension;Liver function test increased;Ocular hyperaemia;Oral discomfort;Vomiting,140243431,HO,,,140243431,1,20170801,20170802,,,140243431,1,Asymptomatic HIV infection
14025378,140253781,1,I,20170801,20170928,20170929,20170929,EXP,GB-MHRA-EYC 00163243,GB-GLAXOSMITHKLINE-GB2017150413,GLAXOSMITHKLINE,,26,YR,,F,Y,68,KG,20170929,,MD,GB,GB,EFAVIRENZ,Acute kidney injury;Feeling hot;Flushing;Hypersensitivity;Hypotension;Liver function test increased;Ocular hyperaemia;Oral discomfort;Vomiting,140253781,HO,,,140253781,1,20170801,20170802,,,140253781,1,Asymptomatic HIV infection
14026571,140265711,1,I,,20170918,20170929,20170929,EXP,,US-CIPLA LTD.-2017US17668,CIPLA,"ALI MS, CIFTCI FD, KOORAGAYALU S, MBA B, KOHLI A, GHORI U ET AL.. AN UNUSUAL COMPLICATION OF INHALED CORTICOSTEROIDS IN AN HIV INFECTED PATIENT. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2017;195",,,,,Y,,,20170929,,MD,US,US,EFAVIRENZ,Drug interaction;Fall;Myopathy;Toxicity to various agents,140265711,HO,,,,,,,,,140265711,1,Chronic obstructive pulmonary disease
14028106,140281061,1,I,,,20170929,20170929,DIR,US-FDA-385008,,FDA-CTU,,,,,M,N,67.5,KG,20170929,N,PH,US,US,efavirenz,Diarrhoea;Fatigue;Pyrexia;Weight decreased,,,140281061,HP,140281061,1,20170213,20170406,,,140281061,1,HIV infection
6305804,630580411,11,F,20000318,20170711,20070507,20170802,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13769260,BRISTOL MYERS SQUIBB,,24,YR,,M,Y,,,20170802,,CN,JP,JP,EFAVIRENZ,Dizziness;Palpitations;Pulmonary hypertension,630580411,DS,,,630580411,1,19941119,20040514,,,630580411,1,HIV infection
6464949,64649492,2,F,,20071031,20071113,20170706,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13975370,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20170706,,CN,US,US,EFAVIRENZ,Lactic acidosis;Pancreatitis haemorrhagic,64649492,DE,,,,,,,,,64649492,1,Product used for unknown indication
6464950,64649502,2,F,,20071031,20071113,20170706,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13975404,BRISTOL MYERS SQUIBB,,40,YR,,F,Y,91.5,KG,20170706,,CN,US,US,EFAVIRENZ,Lactic acidosis;Pancreatitis haemorrhagic,64649502,DE,,,,,,,,,64649502,1,Product used for unknown indication
6465148,64651482,2,F,,20071031,20071113,20170706,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13976840,BRISTOL MYERS SQUIBB,,46,YR,,F,Y,63,KG,20170706,,CN,US,US,EFAVIRENZ,Lactic acidosis,64651482,OT,,,,,,,,,64651482,1,Product used for unknown indication
6465474,64654742,2,F,,20071031,20071113,20170706,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13976824,BRISTOL MYERS SQUIBB,,46,YR,,F,Y,100,KG,20170706,,CN,US,US,EFAVIRENZ,Lactic acidosis,64654742,OT,,,,,,,,,64654742,1,Product used for unknown indication
6465481,64654812,2,F,,20071031,20071113,20170706,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13976832,BRISTOL MYERS SQUIBB,,53,YR,,F,Y,79.9,KG,20170706,,CN,US,US,EFAVIRENZ,Hyperlactacidaemia,64654812,LT,,,,,,,,,64654812,1,Product used for unknown indication
6465660,64656602,2,F,,20071031,20071113,20170706,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13975396,BRISTOL MYERS SQUIBB,,54,YR,,F,Y,97,KG,20170706,,CN,US,US,EFAVIRENZ,Lactic acidosis;Pancreatitis haemorrhagic,64656602,DE,,,,,,,,,64656602,1,Product used for unknown indication
6468236,64682362,2,F,,20071031,20071114,20170706,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13976865,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,65,KG,20170706,,CN,US,US,EFAVIRENZ,Hyperlactacidaemia,64682362,LT,,,,,,,,,64682362,1,Product used for unknown indication
6870591,68705912,2,F,,20170823,20081231,20170831,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14455729,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20170831,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,68705912,OT,,,68705912,1,2004,,,,68705912,1,Product used for unknown indication
8691284,869128410,10,F,20090824,20170719,20120730,20170726,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-16789448,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,,,20170726,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Full blood count decreased;Hepatitis C,869128410,OT,,,869128410,1,20000901,20100711,,,869128410,1,HIV infection
